

University of Dundee

**British Association of Dermatologists and British Photodermatology Group guidelines for the safe and effective use of psoralen-ultraviolet A therapy 2015**

Ling, T. C.; Clayton, T. H.; Crawley, J.; Exton, L. S.; Goulden, V.; Ibbotson, S.

*Published in:*  
British Journal of Dermatology

*DOI:*  
[10.1111/bjd.14317](https://doi.org/10.1111/bjd.14317)

*Publication date:*  
2016

*Document Version*  
Peer reviewed version

[Link to publication in Discovery Research Portal](#)

*Citation for published version (APA):*

Ling, T. C., Clayton, T. H., Crawley, J., Exton, L. S., Goulden, V., Ibbotson, S., McKenna, K., Mohd Mustapa, M. F., Rhodes, L. E., Sarkany, R., & Dawe, R. S. (2016). British Association of Dermatologists and British Photodermatology Group guidelines for the safe and effective use of psoralen-ultraviolet A therapy 2015. *British Journal of Dermatology*, 174(1), 24-55. [14317]. <https://doi.org/10.1111/bjd.14317>

**General rights**

Copyright and moral rights for the publications made accessible in Discovery Research Portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from Discovery Research Portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain.
- You may freely distribute the URL identifying the publication in the public portal.

**Take down policy**

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

This is the peer reviewed version of the following article: Ling, T.C., Clayton, T.H., Crawley, J., Exton, L.S., Goulden, V., Ibbotson, S., McKenna, K., Mohd Mustapa, M.F., Rhodes, L.E., Sarkany, R. and Dawe, R.S. (2016), British Association of Dermatologists and British Photodermatology Group guidelines for the safe and effective use of psoralen–ultraviolet A therapy 2015. *Br J Dermatol*, 174: 24–55., which has been published in final form at doi:10.1111/bjd.14317. This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Self-Archiving.

## **British Association of Dermatologists and British Photodermatology Group guidelines for the safe and effective use of PUVA therapy 2015**

TC Ling, TH Clayton, J Crawley, \* LS Exton,† V Goulden,‡ S Ibbotson,§ K McKenna,¶ MF Mohd Mustapa,† LE Rhodes,™ R Sarkany, \* RS Dawe§

Dermatology Centre, Salford Royal NHS Foundation Trust, Salford, Manchester M6 8HD; \*Department of Dermatology, University College Hospital, 235 Euston Road, London NW1 2BU; †British Association of Dermatologists, Willan House, 4 Fitzroy Square, London, W1T5HQ; ‡Department of Dermatology, Leeds Teaching Hospitals NHS Trust, Leeds, West Yorkshire LS7 4SA; §Department of Dermatology, Ninewells Hospital & Medical School, University of Dundee, Dundee DD1 9SY; ¶Department of Dermatology, Belfast City Hospital, Belfast BT9 7AB; ™Dermatology Research Centre, Faculty of Medical and Human Sciences, University of Manchester, Salford Royal Foundation Trust, Manchester M6 8HD

### **Corresponding author:**

Tsui Ling, [Tsui.Ling@srft.nhs.uk](mailto:Tsui.Ling@srft.nhs.uk); [guidelines@bad.org.uk](mailto:guidelines@bad.org.uk)

TCL, THC, JC, VG, SI, KMCK, LER, RS and RSD are members of the guideline development group with technical support from LSE and MFMM.

### **Footnote:**

*This is an updated set of guidelines prepared for the British Association of Dermatologists' (BAD) Clinical Standards Unit, which includes the Therapy & Guidelines Sub-committee. Members of the Clinical Standards Unit that have been involved are: PM McHenry [Chairman T&G], JR Hughes, M Griffiths, AJ McDonagh, DA Buckley, I Nasr, VJ Swale, CE Duarte Williamson, NJ Levell, T Leslie, E Mallon, S Wakelin, P Hunasehally, MJ Cork, S Ungureanu, J Donnelly [British National Formulary], K Towers [British National Formulary], C Saunders [British Dermatological Nursing Group], R Davis [British Dermatological Nursing Group], AG Brain [BAD Scientific Administrator], LS Exton [BAD Information Scientist], MF Mohd Mustapa [BAD Clinical Standards Manager].*

**These guidelines were first produced by the British Photodermatology Group in 1994 (oral PUVA) and in 2000 (topical PUVA)**

**This update was produced jointly by the British Photodermatology Group and the British Association of Dermatologists**

### **Conflicts of interest:**

THC (1) advisory board payment – Johnson & Johnson (non-specific); (2) conference organising fee – Galderma (non-specific); SI (1) travel expenses and honoraria – Galderma, Spirit and Ambicare Health (non-specific); (2) research support – Ambicare Health (non-specific)

**Key words:** photochemotherapy; phototherapy; psoralens; PUVA; guidelines; treatment; safety.



NICE has accredited the process used by the British Association of Dermatologists to produce guidelines. Accreditation is valid for 5 years from May 2010. More information on accreditation can be viewed at [www.nice.org.uk/accreditation](http://www.nice.org.uk/accreditation). For full details of our accreditation visit: [www.nice.org.uk/accreditation](http://www.nice.org.uk/accreditation).

## 1.0 PURPOSE AND SCOPE

The overall objective of the guidelines is to provide up-to-date, evidence-based recommendations for the use of Psoralen-ultraviolet A photochemotherapy (PUVA) therapy. The document aims to update and expand on the previous guidelines by:

- offering an appraisal of all relevant literature since 1990, focusing on any key developments
- addressing important, practical clinical questions relating to the primary guideline objective
- providing guideline recommendations and, where appropriate, with some health economic implications
- discussing potential developments and future directions

The guideline is presented as a detailed review with highlighted recommendations for practical use in the clinic (see section 15.0), in addition to the production of a Patient Information Leaflet (PIL; available on the BAD website, [www.bad.org.uk](http://www.bad.org.uk)).

## 2.0 STAKEHOLDER INVOLVEMENT AND PEER REVIEW

The initial guideline development group (GDG) consisted of consultant dermatologists, a medical physicist, a nurse phototherapist and a clinical fellow in medical dermatology. The draft document was circulated to the BAD membership, the British Photodermatology Group (BPG) membership, British Dermatological Nursing Group (BDNG), National Eczema Society (NES), Vitiligo Society, Psoriasis Association, and Psoriasis and Psoriatic Arthritis Alliance for comments, which were actively considered by the GDG and peer-reviewed by the Clinical Standards Unit of the BAD (made up of the Therapy & Guidelines Sub-committee) prior to publication.

## 3.0 METHODOLOGY

This set of guidelines has been developed using the British Association of Dermatologists' (BAD) recommended methodology<sup>1</sup> and with reference to the Appraisal of Guidelines Research and Evaluation (AGREE II) instrument.<sup>2</sup> [www.agreetrust.org](http://www.agreetrust.org) Recommendations were developed for implementation in the NHS using a process of considered judgment based on the evidence. PubMed, MEDLINE and EMBASE databases were searched up to December 2014 for meta-analyses, randomised and non-randomised (controlled) clinical trials, case series, case reports, and open and cohort studies involving PUVA therapy published in the English language; search terms and strategies are detailed as a web appendix. Additional

relevant references were also isolated from citations in reviewed literature, as well as (independent) targeted searches carried out by co-authors. The authors screened the identified titles and those relevant for first-round inclusion were selected for further scrutiny. The abstracts for the shortlisted references were then reviewed and the full papers of relevant material were obtained. The structure of the guidelines published in 2000 was discussed and re-evaluated, and different co-authors were allocated separate sub-sections. Each co-author performed a detailed appraisal of the selected literature with discussions with the entire development group to resolve any issues, e.g. with the quality of evidence and making the appropriate recommendations. When considered helpful to assist with comparing study results and summarize data, forest plots drawn in Microsoft Excel were used,<sup>3</sup> although no formal meta-analyses were performed to prepare these guidelines. All sub-sections were subsequently collated and edited to produce the final guidelines.

#### 4.0 LIMITATIONS OF THE GUIDELINE

This document has been prepared on behalf of the BAD and is based on the best data available when the document was prepared. It is recognized that under certain conditions it may be necessary to deviate from the guidelines and that the results of future studies may require some of the recommendations herein to be changed. Failure to adhere to these guidelines should not necessarily be considered negligent, nor should adherence to these recommendations constitute a defence against a claim of negligence. Limiting the review to English language references was a pragmatic decision but the authors recognise this may exclude some important information published in other languages.

#### 5.0 PLANS FOR GUIDELINE REVISION

The proposed revision date for this set of recommendations is scheduled for 2020; where necessary, important interim changes will be updated on the BAD website.

#### 6.0 INTRODUCTION AND HISTORY

PUVA has been in use with refined psoralens since the early 1950s.<sup>4</sup> Its use has declined somewhat as narrowband ultraviolet B (NB-UVB) replaced less effective broadband ultraviolet B (BB-UVB) sources to treat psoriasis and as NB-UVB has been proved more effective than PUVA to treat vitiligo.<sup>5,6</sup> It remains an important treatment; being the first-line phototherapy for pityriasis rubra pilaris and plaque stage mycosis fungoides and a good second-line phototherapy for common chronic dermatoses including psoriasis, for which it may be more effective than other interventions such as the new biological therapies,<sup>7</sup> atopic eczema and chronic urticaria. For phototherapy units serving small populations the availability of NB-UVB should be the first priority, but all larger phototherapy units should be able to offer PUVA.

#### 7.0 ORAL AND TOPICAL PUVA: THE DIFFERENT FORMS AVAILABLE

There are many different forms of PUVA. Different psoralens are available (8-methoxypsoralen (8-MOP), 5-methoxypsoralen (5-MOP), trimethylpsoralen) and other similar furocoumarin compounds (such as khellin) are also used in some areas. The psoralens may be applied topically (as soaks, whole-body, except head and neck, in a bathwater psoralen liquid [bath PUVA], as cream, as gel, as lotion) and by mouth (using different formulations including microcrystalline tablets and liquid in capsules). Also, different ultraviolet A (UVA) sources are used including fluorescent BB-UVA lamps, metal halide BB-UVA lamps and sunlight. In the UK, oral PUVA typically involves administration of microcrystalline tablet oral 8-MOP dosed according to estimated body surface area followed 2 hours later by exposure to fluorescent BB-UVA lamps.<sup>8</sup> Usually, oral 5-MOP (which is more costly and has been less studied) is used if excessive nausea occurs with oral 8-MOP.

## 8.0 EFFECTIVE USE OF PUVA: REVIEW OF THE EVIDENCE

### 8.1 When should patients be treated with PUVA?

For most indications PUVA is a skin-targeted immunosuppressive treatment; other mechanisms of action are also of likely importance. Many conditions that can be treated with PUVA can also be treated with NB-UVB. NB-UVB is a simpler treatment, with fewer side effects to consider, so PUVA is generally indicated for chronic plaque psoriasis and atopic eczema if NB-UVB has not been effective. In such cases PUVA is often successful: failure to respond adequately to NB-UVB does not predict failure of response to PUVA. For some indications PUVA is the first-line phototherapy (favoured over NB-UVB). These indications include mycosis fungoides beyond patch stage, pustular psoriasis, pompholyx, hand and foot eczema and, probably, adult generalised pityriasis rubra pilaris.<sup>9</sup>

**Commented [LE1]:** All subsequent references have been renumbered

### 8.2 Selection of oral PUVA or topical PUVA (Table 1)

In practice the choice of route of psoralen administration is usually based on patient preference. Many patients prefer oral PUVA as it involves less time in the hospital unit, but some choose topical PUVA, in particular to avoid the inconvenience of eye protection.

## 9.0 PUVA FOR SPECIFIC DERMATOSES

### 9.1 Psoriasis

#### 9.1.1 Is oral PUVA therapy more effective than topical PUVA in patients with chronic plaque psoriasis?

Two randomised parallel group studies compared oral 8-MOP PUVA with 8-MOP bath PUVA.<sup>10,11</sup> One prospective contemporaneous controlled (but not reported to be randomised) study compared oral 8-MOP PUVA with trioxsalen (trimethylpsoralen, TMP) bath PUVA<sup>12</sup> and another compared oral 8-MOP PUVA with 8-MOP bath PUVA.<sup>13</sup> None of these studies (**Table 2**) detected a definite difference in efficacy between oral and bath PUVA (**Figure 1**), although one did show 18% more of the small study sample population clearing with bath than with oral PUVA<sup>11</sup> (**Figure 1**). A recently published randomised study comparing bath 8-MOP PUVA with oral 8-MOP PUVA for psoriasis did not detect a difference in efficacy between these modalities.<sup>14</sup> One study report included a questionnaire administered to 13 patients who had

received both oral and bath PUVA. There was a roughly equal split amongst these patients in which form of PUVA they favoured. A recent questionnaire survey of patients referred to a UK phototherapy unit found a similar, roughly equal, split between patients who would choose bath PUVA and those who would choose oral PUVA.<sup>15</sup>

Oral PUVA was not more effective than topical PUVA as a whole-body treatment for psoriasis. The evidence which exists from randomised controlled trials (RCTs) and prospective contemporaneous non-randomised controlled studies showed that bath PUVA works at least as well as oral PUVA. It is of value to be able to offer bath PUVA as well as oral PUVA.

**Recommendation: (Strength of recommendation B; level of evidence 1+)**

- All dermatology phototherapy units should offer bath PUVA as well as oral PUVA to treat psoriasis.

#### **9.1.2 Is PUVA therapy more efficacious than conventional oral systemic therapies in patients with chronic plaque psoriasis?**

There have been no RCTs comparing conventional oral systemic therapies with PUVA to treat chronic plaque psoriasis. An RCT compared PUVA with placebo (**Figure 2**)<sup>16</sup> and showed a similar magnitude of benefit as has been shown of various conventional systemic therapies when compared with placebo (**Figure 3**).<sup>17-19</sup> Due to differences in study methodologies, a meta-analysis comparing PUVA with conventional systemic therapies would not be appropriate. Nevertheless, the information given in these publications concerning baseline psoriasis severity suggests that PUVA was likely to be at least of similar efficacy in the relatively short term as these systemics. As the risks with PUVA are lower than the risks with systemic therapy,<sup>20,21</sup> PUVA should usually be considered first.

**Recommendation: (Strength of recommendation B; level of evidence 1+)**

- PUVA should usually be offered before oral systemic therapy for patients with chronic plaque psoriasis that has not responded adequately to other therapies including narrowband UVB.

#### **9.1.3 Is PUVA therapy more efficacious than biologics in patients with chronic plaque psoriasis?**

This has not been assessed in any head-to-head comparative studies. However, a retrospective database comparison showed PUVA in the short term to be more effective than most biologics in improving psoriasis by reducing a psoriasis severity score (PASI) by 75% (PASI 75) (**Figure 4**), and even more so in reducing the PASI by 90% (**Figure 5**).<sup>7</sup>

Some national guidelines on use of biological therapy for psoriasis do not clearly indicate if PUVA should be used before biologics. For example, some guidelines stated that one of the criteria for using biological therapy was “where phototherapy and alternative standard systemic therapy are contraindicated or cannot be used due to the development of, or risk of developing, clinically important treatment related toxicity”, not clarifying whether phototherapy should be taken to include PUVA or not.<sup>22</sup>

A randomised comparative study, of adequate duration comparing PUVA with biological therapy would help guidance with prescribing PUVA before biological or not, taking into consideration the relative risks and efficacy. However, on current evidence it seems appropriate to continue to follow the advice in the British National Formulary<sup>23</sup> where PUVA should be considered before biological therapy.

**Recommendation: (Strength of recommendation C; level of evidence 2+)**

- PUVA should always be considered before biological therapy to treat chronic plaque psoriasis.

**9.1.4 Is PUVA therapy more efficacious than NB-UVB in patients with chronic plaque psoriasis?**

Ten comparative studies of PUVA with NB-UVB to treat psoriasis have been published (**Figure 6**);<sup>24-33</sup> six of these studies were randomised,<sup>26-30,33</sup> with the rest being contemporaneous controlled studies. A study by Dayal *et al.* is not included in **Figure 6** because insufficient data was available in the report although it was reported that all (in both groups) reached “greater than 75% clearance or complete clearance”.<sup>32</sup> One study found that PUVA was more effective the more severe the psoriasis was at baseline<sup>25</sup> and another showed that PUVA remained more effective than NB-UVB at 6 months after completion of treatment courses.<sup>26</sup> In most (but not all) comparisons involving NB-UVB three times a week there was either little difference, or NB-UVB was more effective, whereas in all but one of the studies comparing NB-UVB twice weekly with PUVA, PUVA was more effective (**Figure 6**). A randomised study comparing NB-UVB twice a week with NB-UVB three times a week found 11% more patients in the latter group clearing;<sup>34</sup> possibly those studies comparing twice a week NB-UVB regimens were not comparing optimally effective NB-UVB regimens with PUVA. Only two studies showed NB-UVB to be significantly more effective than PUVA: both used a TMP bath PUVA regimen.<sup>27,29</sup>

Overall, in the UK, PUVA appears more effective than NB-UVB for psoriasis. It may work better in those with more severe psoriasis, although only one study showed this as a significant finding. PUVA can work when NB-UVB has not worked, as found in at least one of the paired comparison studies. The experience of all members of the GDG is that failure to respond adequately (either in initial clearance or maintenance of improvement after a course) to NB-UVB does not mean that PUVA will not prove adequate. An assessment of one region's data corroborates this impression: during the 5 years (2005 to 2009 inclusive), 128 patients had a first course of NB-UVB followed by a first course of PUVA in Tayside. Of these PUVA courses, subsequent to a course of NB-UVB, 62% (70/128) were documented to achieve 'clearance' or 'minimal residual activity' and 56% (29/52) of PUVA courses subsequent to a failed NB-UVB course were documented as achieving 'clearance' or 'minimal residual activity'.

We found no studies directly comparing PUVA with NB-UVB in children.<sup>35</sup> It seems likely that the relative efficacy of these treatments will be similar to that found in adults.

There are greater adverse effect concerns with PUVA than with NB-UVB; with particularly long-term skin cancer risks a concern when treating children for what is frequently a lifelong condition. Also, PUVA is more involved, requiring taking tablets, or attending for baths in a hospital unit. Therefore, PUVA is not a first-line phototherapy for adults, but even less so for

children. However, for individuals who have not adequately responded to NB-UVB it is appropriate to consider it, and for many children it is more appropriate than other options, which may include hospital admissions resulting in disruption of school and home life or systemic therapies with their adverse effect risks.

**Recommendation: (Strength of recommendation B; level of evidence 1+)**

- Although PUVA may occasionally be appropriate as a first-line phototherapy treatment for especially thick and/or extensive plaque psoriasis it should usually only be considered in patients with chronic plaque psoriasis if NB-UVB has not been adequately effective.

## **9.2 Eczema**

We did not find any controlled studies investigating the use of PUVA in atopic eczema. The findings of several uncontrolled studies have suggested that PUVA is an effective treatment for severe atopic eczema.<sup>36,37</sup> A more recent randomised crossover trial found 5-MOP plus UVA to be superior to medium dose UVA1 in the treatment of severe atopic eczema.<sup>38</sup> The authors also found that reductions in an eczema severity score were observed after only ten irradiations.

A systematic review on the use of photo(chemo)therapy in the management of atopic eczema found good quality RCTs to be limited with PUVA therapy.<sup>39</sup>

### **9.2.1 Is PUVA therapy more efficacious than narrowband UVB in patients with atopic eczema?**

We found no prospective trials comparing PUVA and NB-UVB. The efficacy of 8-MOP bath-PUVA versus NB-UVB has been studied in a half-side comparison study.<sup>40</sup> The authors of this small study concluded that both regimens were not detectably different in efficacy. In the absence of strong evidence favouring PUVA, NB-UVB should be the first-line phototherapy for atopic eczema as a simpler and safer intervention.

**Recommendation: (Strength of recommendation D; level of evidence 3)**

- PUVA should be considered in patients with atopic eczema only if NB-UVB has not been adequately effective.

### **9.2.2 Is PUVA therapy more efficacious than conventional oral systemic therapies in patients with atopic eczema?**

There were no direct comparative trials comparing systemic agents with PUVA in patients with atopic eczema.

### **9.2.3 Is PUVA therapy more efficacious than narrowband UVB in children (younger than 16) with eczema?**

Whilst there were several retrospective studies showing efficacy of PUVA in children with atopic eczema, there were no direct comparative studies comparing PUVA with NB-UVB in children. A large study of 113 Japanese patients with severe atopic eczema treated with oral PUVA, which included 18 patients aged 12 to 19 years, reported that the majority of patients improved with PUVA,<sup>36</sup> although only 31 subjects were scored for severity. The efficacy of



bath PUVA therapy in severe cases of atopic dermatitis (AD) in adults has been studied in children over 12 years.<sup>41</sup> This small study of 30 subjects reported patient evaluations with an overall patient satisfaction score of 8.8 on a scale of 0 to 10.

The most convincing evidence for the use of PUVA in children with atopic eczema came from a report by Sheehan *et al.* who described 32 of 39 children able to achieve remission.<sup>42</sup> Similar results have been reported for the use of UVB in children with atopic eczema.<sup>43</sup>

### 9.3 Cutaneous T cell lymphoma

PUVA remains a major therapeutic modality in the treatment of cutaneous T cell lymphoma (CTCL). Its use is in the treatment of the commonest form of CTCL, mycosis fungoides (MF), where it remains the major therapy for plaque-stage disease. PUVA phototoxicity has been shown to target selectively neoplastic T lymphocytes in the skin.<sup>44-48</sup>

#### 9.3.1 How does PUVA compare to other types of phototherapy in CTCL?

##### a. Narrowband UVB (TL-01) compared to PUVA

There are no double-blinded, controlled comparison trials of PUVA versus NB-UVB for the treatment of early stage CTCL, and most data is from retrospective studies. These show similar remission rates of 50% to 81% for UVB, and 64% to 71% for PUVA [Refer to online journal for more details].

##### b. Other types of phototherapy

###### i. Broadband UVB (BB-UVB):

There are no comparative studies of BB-UVB against PUVA in CTCL. Like NB-UVB, the role of BB-UVB in CTCL appears to be in early stage disease.<sup>49,50</sup>

###### ii. UVA-1

There are no comparative studies of UVA1 versus PUVA. There is limited data regarding UVA1 therapy in CTCL, and this suggests that it potentially may be a useful treatment in patch-stage disease<sup>51</sup> and perhaps in more advanced disease as well.<sup>52</sup>

#### Recommendation: (*Strength of recommendation D; level of evidence 3*)

- For patch-stage CTCL, NB-UVB is as effective as PUVA and is the treatment of choice.

#### Recommendation: (*Strength of recommendation D; level of evidence 4*)

- For plaque-stage CTCL, PUVA is the treatment of choice.

#### 9.3.2 When should PUVA be used in CTCL?

PUVA is very effective in clearing lesions of early-stage CTCL, i.e. patches and thin plaques. Its effect on infiltrative thick lesions and tumours is more controversial.<sup>53</sup> Since patch stage disease is so responsive to NB-UVB, PUVA's role is primarily in the treatment of plaque-stage disease. However, one must be aware and use caution in this setting, knowing that there may be an increased risk of other skin tumours if immunosuppressive agents are required later in

the disease process.<sup>54</sup> It is not always possible to predict in advance who might require systemic immunosuppressive therapies later and progressing to next-line therapies earlier rather than PUVA is often not appropriate. The issues should be fully discussed with patients.

For more details of PUVA studies in CTCL, please refer to the online journal.

Flexural sites ('sanctuary sites') often fail to respond completely - in both patch and plaque stages - and the duration of response varies.<sup>55</sup>

Trial evidence of the role of PUVA in late-stage disease is more limited but nevertheless suggestive that PUVA, as a monotherapy, is not an effective therapy in late-stage disease.

Treatment schedules vary in studies of PUVA from twice to four times a week with varied increment protocols. In the UK, commonly used schedules are two- to three-times-a-week treatments until disease clearance or best partial response.<sup>55</sup> Unlike in most other conditions treated with phototherapy, maintenance therapy to prevent disease relapse in patients with quickly recurrent disease is still common practice.<sup>56</sup> There is, however, no consensus on this (and a trial comparing maintenance versus no maintenance in PUVA for MF is ongoing [Clinical Trials Registry, NCT01686594]) and the benefits of maintenance therapy are still uncertain. Whittaker *et al.* concluded that maintenance PUVA therapy should be avoided and the cumulative lifetime PUVA exposure should be limited (1200 J/cm<sup>2</sup> of UVA and/or 250 sessions) (Whittaker *et al.* BAD skin lymphoma guidelines. In preparation)

**Recommendation: (Strength of recommendation B; level of evidence 1+)**

- PUVA is the first-line treatment for plaque-stage MF.

**Recommendation: (Strength of recommendation D(GPP); level of evidence 4)**

- Maintenance therapy may be considered to prevent relapse in quickly-recurrent disease.

### 9.3.3 When should PUVA be used with other therapies?

In practice, PUVA is often used with other therapies rather than as monotherapy, as follows [Refer to online journal for more details]:

- PUVA with interferon
- PUVA with retinoids and rexinoids
- PUVA following Total Skin Electron Beam therapy (TSEB)

**Recommendation: (Strength of recommendation B; level of evidence 1+)**

- In the treatment of early-stage CTCL, combination therapy with PUVA and interferon or retinoids/rexinoids should be considered, if the response to monotherapy is slow.

## 9.4 Vitiligo

#### 9.4.1 Is PUVA therapy more efficacious than narrowband UVB in patients with vitiligo?

No; NB-UVB is at least as effective as PUVA in treating vitiligo (**Figure 7**).<sup>6,57,58</sup> Also, the match of repigmentation to normal skin colour is better with NB-UVB than with PUVA,<sup>6</sup> and NB-UVB is more effective in inducing repigmentation in unstable vitiligo than is PUVA.<sup>58,59</sup> These studies involved widespread vitiligo vulgaris; there is no available good quality evidence comparing PUVA and NB-UVB for other patterns of vitiligo, such as segmental vitiligo.

**Recommendation: (Strength of recommendation A; level of evidence 1+)**

- PUVA should only be considered for widespread vitiligo if NB-UVB has not shown to be adequately effective.

#### 9.5 Photodermatoses

Due to the relative rarity of some idiopathic photodermatoses and paucity of evidence in this area, the literature search was extended to include all papers from 1966. Both oral and topical PUVA have been reported to be used in the following idiopathic photodermatoses: polymorphic light eruption (PLE), chronic actinic dermatitis (CAD), solar urticaria (SU), erythropoietic protoporphyria (EPP), and actinic prurigo (AP). Most papers were found in PLE (n = 15), followed by SU (n = 8), CAD (n = 7), AP (n = 2) and EPP (n = 2).

##### 9.5.1 In the treatment of photodermatoses, what is the efficacy and safety of PUVA compared to UVB?

###### a. PLE

In PLE, the reported efficacy of PUVA was 65% to 100% photoprotection rate.<sup>60-71</sup> There were five comparative studies with UVB,<sup>60,61,63,65,66</sup> including two RCTs.<sup>63,65</sup>

The only RCT comparing PUVA with NB-UVB did not detect any significant difference in efficacy. In this trial, 12 patients treated with oral 5-MOP or 8-MOP PUVA were compared with 13 patients treated with UVB and placebo tablets [first dose was 70% minimal phototoxic dose (MPD)/minimal erythema dose (MED); 20% increments; thrice weekly UV exposures for 5 weeks]. The study found no significant differences between the two forms of phototherapy in reducing the number of episodes of PLE or restriction of outdoor activity.<sup>63</sup>

There were two studies that compared the efficacy of PUVA with BB-UVB.<sup>65,66</sup> In an RCT, oral 8-MOP PUVA (n = 13) was compared with BB-UVB plus placebo tablets (n = 13) and low-dose UVA plus placebo tablets (n = 12).<sup>65</sup> Using self-assessment of treatment efficacy, 92% of patients considered PUVA successful compared with 62% with BB-UVB. These findings were supported by Addo *et al.*, who reported complete remission in 89% of patients treated with PUVA compared with 69% treated with BB-UVB.<sup>66</sup>

Man *et al.* reported a 10-year retrospective review of 170 patients with moderate-to-severe PLE who attended for PUVA and/or UVB phototherapy.<sup>60</sup> Eight patients received PUVA, 128 NB-UVB, five BB-UVB and 29 patients who failed to respond satisfactorily

to NB-UVB were given PUVA the following year. The patients were followed up in autumn or the following spring and self-assessments were made of the severity and frequency of PLE episodes. Two hundred and eighty-one courses of UVB and 99 courses of PUVA were evaluated. At follow-up, 88% of those who received PUVA and 89% who received UVB reported good or moderate improvement, and of the 29 who received both PUVA and NB-UVB, 12 favoured PUVA, four preferred NB-UVB, and five responded equally well.<sup>60</sup>

Mastalier *et al.* presented 14-year retrospective data on 79 patients treated with phototherapy; 17 patients with oral 5-MOP or topical 8-MOP PUVA, 56 with BB-UVB, and six with UVA alone. The patients were assessed on the first summer after phototherapy for prevention of PLE episodes. The photoprotection rate was complete/partial remission in 65% for PUVA, 82% for BB-UVB, and 83% for UVA. However, the authors acknowledged that PUVA was given to patients with more severe symptoms, while BB-UVB and UVA alone were given to patients with milder symptoms.<sup>61</sup>

The latter two studies were retrospective chart review studies, with smaller numbers of patients receiving PUVA compared to UVB; moreover, patients who had more severe PLE, or who had previously failed UVB tended to receive PUVA.<sup>60,61</sup>

**i. Safety of PUVA compared to UVB in PLE**

There is an inherent risk of provoking the underlying condition in treating any photodermatosis. There was limited comparative data between the two forms of phototherapy to ascertain which form is more likely to provoke the eruption. Pooling the incidence of adverse events from the small number of PLE studies, the side effects of rash provocation, erythema and pruritus were found to be common in both forms of phototherapy, though commoner with UVB than with PUVA (**Table 3**). However, as the number of patients in each cohort was small and the severity of the adverse events not directly comparable, the overall percentages should be regarded with caution.

In the treatment of PLE, the side effects of rash provocation, erythema and pruritus were found to be common in both forms of phototherapy. There was no appreciable difference in the efficacy of PUVA and UVB.

**b. Photodermatoses other than PLE**

No comparative studies with UVB were identified for the other photodermatoses.

**9.5.2 When should PUVA be used in preference to other therapies for photodermatoses?**

Photodermatoses are chronic conditions requiring ongoing treatment. Photoprotective measures and symptomatic treatment may be adequate in milder cases; however, in more severely affected patients, second-line treatments are often required. First-line treatment may include topical corticosteroids, antihistamines, beta-carotene (for EPP) and is not within the scope of this guideline. Second-line treatment may include phototherapy. NB-UVB is generally considered before PUVA, because it has the following advantages: lower risk of photocarcinogenesis, no risk of nausea or other side effects with ingestion of MOP and

increased convenience as there is no need for taking tablets or using eye protection post-treatment.

**a. PLE**

There is good evidence of efficacy with UVB as compared with PUVA.<sup>63</sup> There are no other direct comparative studies with other modalities of treatment, which include systemic corticosteroid,<sup>72</sup> azathioprine,<sup>73</sup> ciclosporin,<sup>74</sup> hydroxychloroquine,<sup>75,76</sup> beta-carotene,<sup>77-79</sup> nicotinamide,<sup>80,81</sup> omega-3 fatty acids,<sup>82</sup> antioxidants<sup>83-85</sup> and *E. coli* infiltrate.<sup>86</sup> Systemic corticosteroid has been demonstrated to reduce the severity of PLE when used as a short course on sunny holidays.<sup>87</sup> Systemic immunosuppression is effective in a small number of case reports. Efficacy of treatment with hydroxychloroquine, beta-carotene, nicotinamide, omega-3 fatty acids, antioxidants, and *E. coli* infiltrate has not been well established in RCT.

**Recommendation: (Strength of recommendation D; level of evidence 4)**

- In the treatment of PLE, NB-UVB should be considered before PUVA. However, PUVA should be considered if NB-UVB has failed, or has previously triggered the eruption, or if there are other practical issues. PUVA should be considered before other systemic treatments.

**b. Chronic actinic dermatitis (CAD)**

We found no comparative studies using PUVA in the treatment of CAD. There are a limited number of case reports and small case series reporting the use of PUVA in CAD.<sup>88-94</sup> These studies include the use of PUVA under cover with topical or oral corticosteroid, and concomitant use of ciclosporin (cyclosporin) and mycophenolate mofetil [Refer to online journal for more details].

One tertiary referral unit in the UK routinely treats CAD patients with PUVA with success ([personal communication, Garibaldinos T, Guy's and St Thomas' Hospital, London](#)). Prednisolone (20 to 30 mg) is taken on the day of phototherapy; small-dose increments of 0.05 J/cm<sup>2</sup> is given with each UVA-exposure; the course is given three times a week, then stepped down to twice weekly and then once weekly. Inpatient supervision is not generally required.

**Recommendation: (Strength of recommendation D; level of evidence 4)**

- In the treatment of CAD, PUVA therapy should be considered in a specialist unit experienced with managing this disease, with full knowledge of the individual patient's action spectrum. Special precautions including inpatient supervision and topical/oral corticosteroid cover may be required.

**c. Idiopathic solar urticaria (SU)**

We found no comparative studies with PUVA in the treatment of SU.

PUVA has been used in small case series as monotherapy (n = 4; n = 6),<sup>66,95</sup> in combination with intravenous immunoglobulins (single case reports)<sup>96</sup> and with plasmapheresis.<sup>97,98</sup> [Refer to online journal for more details]

Antihistamines are regarded as the standard therapy in SU (other than photoprotection); RCTs are not available in SU itself and it is reported that a substantial proportion of these patients receive only modest benefit.<sup>99-101</sup> High-dose H1 antihistamines are frequently prescribed, in line with published research and recommendations made in general for other chronic urticarias.<sup>102</sup>

NB-UVB has also been reported to be helpful in SU (Calzavara-Pinton *et al.* [n = 39], Wolf *et al.* [n = 1], Collins *et al.* [n = 1]).<sup>103-105</sup> [Refer to online journal for more details] There are no comparative trials between NB-UVB and PUVA.

There was limited evidence from small case series on the use of UVA, either administered on its own,<sup>106-108</sup> or as pre-PUVA de-sensitisation.<sup>109</sup> This has been used in patients who have very low MUD for UVA, where PUVA was thought to be unsafe [Refer to online journal for more details]

**Recommendation: (Strength of recommendation D; level of evidence 4)**

- In the management of SU (after full assessment including definition of the action spectrum), PUVA can be considered. The treatment should be carried out with full knowledge of the patient's action spectrum, in a specialist unit experienced with managing this disease.

**d. EPP**

We did not find any comparative trials with PUVA in the treatment of EPP.

There was limited evidence in the use of PUVA in EPP.<sup>110,111</sup> UVB has been reported in small open studies to be effective in EPP (n = 6; n = 1; n = 12).<sup>105,112,113</sup> [Refer to online journal for more details]

PUVA cannot currently be recommended in the treatment of EPP due to lack of evidence and comparative trials with beta-carotene or UVB, and the long-term risks associated with the need for annual treatment on a lifelong basis.

**Recommendation: (Strength of recommendation D; level of evidence 4)**

- PUVA is rarely appropriate in EPP in which NB-UVB is the phototherapy of first choice.

**e. AP**

We did not find any comparative trials of thalidomide or immunosuppressants with PUVA in the treatment of AP.

There was limited evidence of the use of PUVA in AP. UVB has been reported, in a small open study, to be effective in AP (n = 6).<sup>105</sup> [Refer to online journal for more details].

**Recommendation: (Strength of recommendation D; level of evidence 4)**

- NB-UVB may be a safer therapeutic option in terms of phototherapy-associated carcinogenic risk in patients with AP, particularly in children, and should be considered before PUVA.

**9.5.3 What special precautions should be undertaken during PUVA therapy of photodermatoses?**

Photodermatoses run a high risk of provocation with the different forms of phototherapy. Special precautions are required and are described below for the better-reported photodermatoses PLE, CAD and SU. PUVA is usually administered in early spring in temperate countries. The benefit conferred by phototherapy is diminished or lost several weeks post-phototherapy, and post-treatment advice generally includes continued natural sunlight exposure, if tolerable on an individual basis, to keep their resistance to provocation for the rest of summer. As PUVA generally needs to be repeated, the longer-term risk of skin carcinogenesis need to be weighed against the therapeutic benefit and annual desensitization is not usually recommended.

**a. PLE**

The regimens vary between phototherapy centres; most administer 8-MOP, although 5-MOP, oral and bath TMP, have all been used.<sup>60-71</sup> In most of these studies, 8-MOP PUVA was given three times a week for 12 to 20 treatments. Currently in the UK, a twice-weekly regimen is standard. There are no studies comparing the efficacy and safety of twice- and thrice-weekly regimens.

Although there were no studies on the timing of PUVA therapy during the year, this is likely to be an important consideration particularly in temperate climates. If administered too early in the year, the photoprotective effect may have subsided by mid-summer; administered too late, the patient may have already suffered an eruption and PUVA may increase the risk of provocation or further aggravation.

The risk of provoking PLE is high, particularly with the first few PUVA exposures. At least one episode was induced during 12% to 50% of PUVA treatment courses,<sup>60,62-65,68,69,114</sup> which is a little lower than the rates with UVB of 48% to 62%.<sup>60,63</sup> There is evidence that PUVA is as likely as UVB to cause provocation of PLE. Provocation episodes can be managed with potent topical steroid and subsequently lower dose increments, omitting one or two treatments if particularly severe.<sup>60,62,63,68,69</sup> To prevent provocation, one group administered oral prednisolone (40 to 50 mg) for the first 2 weeks of phototherapy,<sup>67</sup> whilst another reported routine prophylactic application of a potent topical steroid after each exposure in UVB phototherapy.<sup>60</sup>

Pruritus was also reported in 18% to 33% patients<sup>63,64</sup> with one group managing this with oral corticosteroid.<sup>64</sup>

Post-treatment advice generally includes continued natural sunlight exposure, ranging from 2 hours weekly<sup>65</sup> to 'cautious exposure, with sunscreens for extended outdoor stay',<sup>60</sup> to 'expose freely to sun'.<sup>67,70</sup>

**b. CAD**

PUVA phototherapy is generally undertaken under close supervision under cover of topical or systemic corticosteroid, as discussed above.<sup>90,91,93,94</sup> Maintenance treatment may be required. Annual repeated courses can be considered but the benefit needs to be balanced against the long-term risk of skin carcinogenicity.

**c. SU**

Treatment of SU with phototherapy can potentially result in provocation, syncope, and anaphylaxis. UVA is often, but not always, a wavelength where there is sensitivity in this disease. The choice of PUVA for SU as a therapy, and the protocol used, will be governed by the action spectrum as determined by monochromator phototesting.

Thus, it is important to determine both the action spectrum of the disorder, in a specialized phototesting unit, and the MUD before starting phototherapy, preferably with the UV source to be used for treatment. The initiating dose should be lower than the MUD. In patients with a very low MUD, UVA alone,<sup>106-108</sup> or pre-PUVA UVA has been used.<sup>109</sup> The amount of photoprotection will subside, and maintenance treatment with PUVA or UVA has been reported.

**Key points:**

- **When using prophylactic phototherapy to treat photodermatoses, the risk of rash provocation is high. The use of topical/oral corticosteroids may be used prophylactically or therapeutically in PLE or CAD.**
- **Phototherapy may be given in spring, or before a sunny holiday, before expected increased natural UV exposure.**
- **Particularly with CAD and SU, the action spectrum should be determined prior to commencement of phototherapy; PUVA should only be carried out in an experienced specialized unit.**
- **With AP and EPP, UVB should be considered before PUVA.**
- **Post-treatment advice of cautious, continued sunlight exposure should be given to maintain the photoprotective effect, but this is dependent on individual tolerance and photoprotection is still needed in very sunny conditions.**

**9.6 Hand and foot dermatoses**

Local PUVA, using both oral and topical psoralens, has been widely used to treat hand and foot dermatoses over the past 25 years and is generally considered an effective therapy. Oral



psoralen is favoured by some patients for convenience (less time spent in a hospital treatment unit) and because there are lower risks of phototoxic reactions. Topical psoralen is favoured by other patients who prefer not to take oral medication and to avoid the potential risks of systemic side effects and/or drug interactions. In addition, the use of eye protection outside the UV irradiation period is not required. Different forms of topical psoralen are in use including soaks, paint, cream, ointment, emulsion and gel. Treatment regimens also vary not only with regard to methods of psoralen application but in the time interval between psoralen application and UVA irradiation. It has previously been shown in a small study that, in unaffected skin of the palms and soles, there is a lag time of approximately 40 minutes between soaking in psoralen solution and maximum UVA sensitivity in the palmar and plantar skin of healthy volunteers.<sup>115</sup> As a result of this, and earlier reports that suggested efficacy in the hand and foot dermatoses of topical psoralens with a 1- to 2-hour delay between psoralen application and UVA exposure but no efficacy in studies with psoralen application immediately before UVA exposure, previous UK guidelines have recommended a delay of at least 30 minutes between immersion and irradiation.<sup>116</sup>

The hand and foot dermatoses comprise three main conditions: eczema, psoriasis and palmoplantar pustulosis.

#### **9.6.1 What is the efficacy of PUVA therapy in patients with hand and foot dermatoses compared to placebo or other active treatments?**

##### **a. Palmoplantar eczema**

Oral PUVA vs UVB: A prospective contemporaneous controlled study (n = 35)<sup>117</sup> showed both treatments to be effective but oral PUVA was superior to UVB, although relapse rate was high. A subsequent smaller study (n = 20) carried out by the same group using a similar design showed similar results.<sup>118</sup>

Oral PUVA alone: Uncontrolled studies with oral PUVA have shown significant improvement or clearance in 81% to 86% of patients with hand and foot eczema,<sup>119,120</sup> with similar good results in smaller case series.<sup>121,122</sup>

Topical PUVA alone: Uncontrolled studies of topical PUVA have suggested this might be effective treatment with clearance or considerable improvement reported in 58% to 81% of dyshidrotic eczema and 50% to 67% of hyperkeratotic eczema.<sup>123-134</sup> However, evidence from comparative studies was less convincing. A left-right, within-patient study (n = 15) with 8-MOP paint versus placebo in dyshidrotic eczema found no difference between the two groups, and no patient achieved clearance.<sup>135</sup> The lack of efficacy was supported by a small controlled study (n = 6) with 20% 8-MOP gel in which no patient cleared.<sup>136</sup>

Topical PUVA vs UVB, UVA1, superficial X-ray therapy, and combination therapy of topical PUVA and iontophoresis: [Refer to online journal for more details] Evidence from RCTs and prospective contemporaneous controlled studies has not demonstrated any difference in efficacy.

In summary, in hand eczema, evidence from two prospective contemporaneous controlled studies have shown PUVA using oral psoralen to be effective and superior to

UVB. Evidence from RCTs and prospective contemporaneous controlled studies has not demonstrated topical PUVA to be more effective than placebo, UVB, UVA1 or superficial X-ray therapy. However, some uncontrolled studies have shown topical PUVA to be associated with good degrees of improvement. All comparative studies lacked the power to detect what might still be important differences between treatments.

**Recommendation: (Strength of recommendation B; level of evidence 2++)**

- PUVA, using oral psoralen should be considered as a treatment for hand and foot eczema. Although the evidence for topical PUVA in palmoplantar eczema is weak, lack of proof of efficacy does not prove no efficacy and in open discussion with patients, it will sometimes be appropriate to consider topical PUVA.

**b. Palmoplantar psoriasis**

We found no comparative studies comparing oral PUVA to placebo or other active treatments, though a small retrospective study (n = 12)<sup>137</sup> and case series (n = 5)<sup>121</sup> report improvement or clearance.

Oral PUVA vs NB-UVB: A large retrospective study (n = 92) concluded oral PUVA and NB-UVB were equally effective. However, assessment and outcome measures were unclear and no statistical analysis was carried out.<sup>138</sup>

Topical PUVA alone: Uncontrolled studies have reported clearance or significant improvement occurring in 58% to 87% of patients treated with topical psoralen.<sup>123,126-128,130,131,139-142</sup>

Topical PUVA vs UVA: In a randomised, left-right, within-patient study in patients with hand and foot dermatoses (psoriasis n = 11), topical PUVA (20% 8-MOP gel) was suggested to be more effective overall compared to UVA, but the results were not analyzed separately according to the different dermatoses investigated.<sup>136</sup> No patient was reported as being cleared in either group.

Topical PUVA vs 308 UVB excimer laser, and NB-UVB: Refer to online journal for more details. The authors of a Cochrane systematic review of NB-UVB phototherapy versus BB-UVB or PUVA for psoriasis identified only one study for the indication and concluded no significant difference between treatments.<sup>143</sup>

In summary, for palmoplantar psoriasis there is some randomised study evidence for topical PUVA, however, these studies were under-powered. Oral PUVA for this indication has not been studied adequately.

**Recommendations: (Strength of Recommendation C; Level of Evidence 2++)**

- PUVA using topical or oral psoralen should be considered as a treatment for palmoplantar psoriasis.

**c. Palmoplantar pustulosis**

Oral PUVA vs no treatment: Oral PUVA has been compared with no treatment in a randomised, within-patient study (n = 22).<sup>144</sup> This showed improvement in 100% of PUVA-treated sites compared with 59% of untreated sites, with 55% and 0% clearance, respectively. In a prospective contemporaneous controlled study (n = 14), improvement was recorded in 64% with oral PUVA and 14% with no treatment.<sup>145</sup> The clearance rate was 21% and 0%, respectively.

Topical PUVA vs placebo: In a double-blinded, randomised, left-right, within-patient study (n = 27),<sup>146</sup> there was no difference in improvement with topical PUVA compared to placebo. The lack of efficacy of topical PUVA was further supported by smaller randomised studies (n = 10, n = 5)<sup>136,147</sup> with clearance rate of only 0% to 10%.

PUVA vs oral retinoids: Two RCTs have compared PUVA to oral retinoids. One study (n = 84) compared two forms of topical PUVA, oral PUVA and etretinate.<sup>148</sup> A total of 12% (4/33) treated with topical methoxsalen cream cleared compared with 70% (14/20) in the etretinate group. None cleared in the oral PUVA and trioxsalen soak group. This suggests etretinate to be more efficacious, but response to PUVA, and in particular oral PUVA, was much lower than in other published studies. Another study comparing oral PUVA to etretinate showed clearance in 21% (3/12) with PUVA versus 17% (3/18) with etretinate.<sup>145</sup>

The authors of a Cochrane systematic review of interventions for palmoplantar pustulosis, which included the controlled studies detailed above, concluded that oral PUVA is an effective intervention for this indication, although the combination of retinoids plus oral PUVA is more effective. No proven benefit has been demonstrated with topical PUVA and no definite benefit of retinoid as a monotherapy over PUVA was established.<sup>149</sup>

**Recommendations: (Strength of Recommendation C; Level of Evidence 2++)**

- Oral PUVA should be considered as a treatment for palmoplantar pustulosis.

**9.6.2 What is the efficacy of oral PUVA compared to topical PUVA therapy in patients with hand and foot dermatoses?**

**a. Palmoplantar eczema**

Two RCTs have compared oral and topical PUVA. Van Coevorden *et al.* performed an open-label RCT (n = 158) comparing oral methoxsalen (as safer for home use than topical psoralens) using a home UVA unit with topical PUVA using trioxsalen soaks in a hospital setting over a 10-week period.<sup>150</sup> The mean hand eczema scores showed a significant reduction of 41% in the oral PUVA group compared with 31% in the topical PUVA group, with no statistically significant difference between the two groups. This improvement was maintained at 8-week follow-up.

A small RCT compared oral 8-MOP versus 8-MOP soak in dyshidrotic eczema (n = 15) and hyperkeratotic eczema (n = 12). This study did not detect a difference in therapeutic efficacy, and that dyshidrotic eczema improved to a greater extent compared to

hyperkeratotic eczema, however, the study was under-powered and does not justify these conclusions.<sup>151</sup>

**b. Palmoplantar psoriasis**

A retrospective review by Hawk *et al.* of oral and topical 8-MOP PUVA in the treatment of patients with hand and foot dermatoses included 18 patients with psoriasis.<sup>152</sup> Fifty 50% (7/14) of patients who received topical PUVA and 50% (2/4) oral PUVA cleared. A small, within-patient, randomised, right-left comparison study compared PUVA using oral oxisoralen versus PUVA using 8-MOP soaks in patients with palmoplantar dermatoses but included only three patients with psoriasis. Oral PUVA was reported to be more effective.<sup>153</sup>

**c. Palmoplantar pustulosis**

Hawk *et al.*'s retrospective review which included 15 patients with palmoplantar pustulosis showed clearance in 67% (4/6) with oral 8-MOP and 33% (3/9) with topical 8-MOP emulsion.<sup>152</sup>

A small, right-left, within-patient comparative study of oral oxisoralen versus 8-MOP soaks in patients with hand and foot dermatoses included five patients with pustulosis. Oral PUVA was reported to be more effective.<sup>153</sup>

Lassus *et al.*'s RCT of two forms of topical and oral PUVA showed clearance rate of 8% (4/51) with topical PUVA compared with 0% (0/13) oral PUVA.<sup>148</sup> PUVA as a whole was disappointing in that study and no difference between the methods of delivering it was detected. A Cochrane review of interventions for palmoplantar pustulosis found only one direct comparison of topical with oral PUVA for this indication.<sup>149</sup>

**Recommendation: (Strength of recommendation D(GPP); Level of evidence 4)**

- Oral PUVA should usually be considered as the first-line PUVA treatment for patients with palmoplantar dermatoses.

**9.6.3 What is the efficacy of PUVA therapy alone compared to PUVA and adjuvant therapies in the hand and foot dermatoses?**

**a. Palmoplantar eczema**

For foot eczema, topical PUVA has been compared in a randomised trial to topical PUVA combined with iontophoresis over an 8-week treatment period and at follow-up 8 weeks later. There was no significant difference in eczema and DLQI scores.<sup>154</sup>

**b. Palmoplantar psoriasis**

There was only one RCT comparing combination therapy with oral PUVA and etretinate versus PUVA and placebo but this included only three patients with psoriasis.<sup>155</sup> No other relevant studies were identified.

**c. Palmoplantar pustulosis**

Three RCTs examined combination therapy with oral PUVA and retinoids compared to PUVA alone. Rosen *et al.*'s RCT showed clearance in 61% (14/23) with combination therapy and 21% (3/14) with PUVA alone.<sup>145</sup> A further RCT comparing oral PUVA-etretinate versus oral PUVA alone showed clearance of 100% (8/8) and 44% (4/9), respectively.<sup>155</sup> An RCT using 8-MOP PUVA lotion found 60% (6/10) clearing with topical PUVA-etretinate compared with 10% (1/10) with topical PUVA alone.<sup>147</sup>

A Cochrane review of the interventions for palmoplantar pustulosis concluded there was evidence for an increased efficacy of retinoids combined with PUVA compared to PUVA used alone.<sup>149</sup>

**Recommendation: (Strength of Recommendation 1+; Level of Evidence A)**

- Unless there are contraindications, the combination of oral PUVA with oral retinoids should be considered as a treatment for palmoplantar pustulosis.

## 10.0 ADVERSE REACTIONS TO PUVA

### 10.1 Acute

#### 10.1.1 Incidence of acute adverse events [Refer to online journal for full discussion].

Both systemic and topical PUVA are generally well tolerated and the acute adverse effects of PUVA are reasonably well documented. The commonest adverse effects are erythema and pruritus, and nausea associated with oral PUVA.<sup>115,156</sup> In early studies of oral PUVA, reported acute adverse events were uncommon, temporary and generally mild. Melski *et al.* analyzed the adverse events from 41,000 oral PUVA treatments given to 1,308 patients.<sup>157</sup> The incidence of adverse events was: erythema 9.8%, pruritus 14%, nausea 3.2%, headaches 2%, dizziness 1.5%. In later large series (n = 3175), the incidence of adverse events reported were higher: erythema 32.4%, pruritus 25.6%, nausea 13.5%, headaches 2%, Köbner reaction in psoriasis 2%.<sup>158,159</sup> PUVA treatment was interrupted due to erythema in 6.8%, and only uncommonly discontinued. Nausea with 8-MOP is a relatively common occurrence but not with 5-MOP<sup>160</sup> and rarely requires discontinuation of treatment.

#### a. Erythema

Studies of the time course of PUVA erythema following both oral and topical PUVA indicate erythema peaking at 96 hours or later in the majority of subjects. Oral 5-MOP PUVA has a similar time course to that of 8-MOP.<sup>161</sup> In practice, many centres use an MPD assessment time of 72 hours and no studies have been undertaken to evaluate whether there are differences in efficacy or adverse effects between treatment regimens based on a 72-hour versus 96-hour MPD assessment. Most UK centres use a twice-weekly regimen for both oral and topical PUVA.

The UVA dose should be delivered within 10 minutes after an 8-MOP bath as photosensitivity reduces quickly, although there may be a more prolonged effect over 40 minutes if palmar and plantar skin are being treated.<sup>116,162</sup> The temperature of the bath for PUVA delivery is also important, with photosensitisation being optimal at 37°C and reduced at lower temperatures.<sup>163</sup>

Unusual patterns of erythema and burning have been reported, particularly with TMP bath PUVA due to the powder formulation of TMP and the variable distribution within the bath water as it forms a micro-crystallized suspension.<sup>164</sup> Frank blisters can also occur either due to over-exposure to UVA or psoralen dose, for example, as seen if patients stand in a particular way in the cabinet.<sup>165</sup> Particular care is needed in patients with vitiligo.<sup>166,167,</sup>

Thus, depending on the methods for reporting erythema, incidence of PUVA erythema during treatment is between 10% and 32%, requiring treatment interruption in between 1% to 7% of cases. Patients of lighter skin phototype and those treated with more frequent treatment regimens are at greatest risk of developing erythema during treatment. Early recognition of cumulative erythema is important and omission of treatment until this has resolved and adjustment of dose increments may be required. Topical emollients and steroids may offer symptomatic relief.

**b. Pruritus**

There seems to be a similar incidence of pruritus following oral and bath PUVA occurring in 10% to 40% of patients.<sup>115,157,159</sup> The incidence of pruritus is reported to be lower with 5-MOP (43.6%) compared with 8-MOP (71.8%).<sup>164</sup> There do not appear to be specific predictors for the likelihood of this adverse effect occurring.

**c. Nausea**

Nausea is relatively common, occurring in about 3% to 13% of patients.<sup>157,159,168</sup> This can be helped by taking the psoralen with a light meal or using an antiemetic. If nausea is significant then 5-MOP or topical psoralen can be used.<sup>168</sup> The incidence of nausea was reported to be much lower with 5-MOP (7.7%) compared with 8-MOP (51%) in one study.<sup>164</sup>

**d. Induction of photodermatoses**

Precipitation or aggravation of photodermatoses which are associated with abnormal UVA photosensitivity can occur with PUVA, with reports of CAD and PLE exacerbation having been observed.<sup>63,169</sup> The rate of inducing PLE was estimated to be 50% compared with 62% with NB-UVB in one study.<sup>63</sup> Theoretically, exacerbation or induction of lupus can occur, and there are case reports of the coincidence of PUVA with the development of lupus.<sup>170-172</sup>

**e. Drug phototoxicity**

Drug phototoxicity in general is not a major problem because of the overwhelming effect of psoralen photosensitisation, and as long as MPD assessment is performed on the patient's drug regimen, this can be largely avoided.<sup>168</sup> However, pseudoporphyria can occur, as with some of the other phototoxic drugs such as the fluoroquinolones, non-steroidals, tetracyclines and diuretics, and is more likely to occur after minor trauma and on acral sites. Furthermore, enhancement of PUVA phototoxicity has been reported after ingestion of celery and vegetable broths during PUVA therapy<sup>173</sup> and after taking Rutaceae extracts and celery soup.<sup>174</sup> Reported phototoxicity rates seem to be similar for oral and bath 8-MOP PUVA,<sup>115</sup> although clinical experience suggests that severe

phototoxic reactions are more likely with bath PUVA. In general, avoiding psoralen-containing plants for at least 2 hours before treatment is advised.

Systemic psoralen can interfere with liver metabolism, which results in many potential drug interactions. Psoralens cause liver enzyme inhibition which in turn causes a potential serum increase of the following: warfarin, anticholinergics, antipsychotics, NSAID, theophylline, caffeine; more frequent monitoring is advised if a patient is on warfarin. The effects of caffeine are augmented by PUVA,<sup>175-177</sup> and can occasionally cause headaches and 'jitteriness' on treatment days. Advice to reduce caffeinated beverage intake on these days may be required. Systemic psoralen can also cause liver enzyme induction which may reduce serum concentration of: ciclosporin, chemotherapy agents, azole antifungals, macrolides, tricyclics, antidepressants and antipsychotics, benzodiazepines, statins, calcium channel blockers, protease inhibitors, oral contraceptives. Co-administration of potent liver enzyme inducers such as phenytoin and carbamazepine may increase metabolism of psoralen and result in a reduced response to PUVA. The risk of potential drug interactions further underscore the importance of MPD testing to ensure patient safety and also an adequate amount of psoralen in the skin at the correct time to allow the wanted phototoxic responses.

**f. Hepatotoxicity**

There are case reports of hepatitis following 5-MOP<sup>178,179</sup> and 8-MOP.<sup>180-183</sup> Importantly, two of the four cases arose in patients who had methotrexate-induced liver damage, and the remaining cases resolved once the drug was stopped. In one study of 162 patients receiving PUVA, only three patients had transient elevations of transaminases which all reverted to normal after treatment was stopped.<sup>184</sup> The rarity of these cases, that have occurred with bath as well as oral PUVA, support the view that routine monitoring of liver function tests is not required. The mechanism is unclear and may be idiosyncratic.<sup>185</sup>

**g. Pain**

Severe skin pain with PUVA is uncommon and was seen in 4% (8/210) of patients treated with oral PUVA in one series.<sup>186</sup> It is characterized by persistent severe prickling, burning or dysaesthesia which can last from minutes to hours and can persist for weeks or months. The risk of developing PUVA pain is unpredictable and does not appear to be related to the patient's skin phototype, PUVA sensitivity or induction of PUVA phototoxicity. An underlying neurogenic mechanism appears most likely.<sup>187-189</sup> Treatment with analgesics, topical anaesthetics and topical or systemic steroids, usually has minimal effect. Capsaicin,<sup>190</sup> gabapentin,<sup>191</sup> phenytoin<sup>188</sup> and low frequency electrotherapy<sup>192</sup> can potentially be of benefit. Once PUVA pain has developed it is then a relative contraindication to further PUVA treatment as it is likely to recur.

**h. Miscellaneous**

Both allergic and photocontact allergic dermatitis to psoralens have been reported to affect 0.8% (3/371) of patients treated with topical PUVA.<sup>193</sup> Type I anaphylaxis to both 5-MOP<sup>194</sup> and 8-MOP<sup>195</sup> has also been observed in isolated cases and asthma may be aggravated.<sup>196-199</sup>

Hyperpigmentation is usually a result of repeated PUVA treatments but may also occur with the concurrent use of topical vitamin D analogues at treated lesional sites,<sup>200,201</sup> and with concomitant treatment with isotretinoin.<sup>202</sup>

Triggering of herpes simplex virus can occur with PUVA and use of high-factor sunscreen on the lips and prophylactic aciclovir for susceptible subjects is recommended. Eczema herpeticum has been reported in a patient with AD treated with PUVA.<sup>203</sup> Folliculitis can occur and can be managed with applying emollients in a downward direction of the hair.

Onycholysis following ingestion of phototoxic drugs is well documented. Onycholysis following ingestion of psoralens and natural sunlight has been observed and has also been reported following PUVA photochemotherapy.<sup>204</sup> Other associated adverse events include lunular changes,<sup>205</sup> subungual haemorrhage<sup>159</sup> and nail pigmentation.<sup>159</sup>

Clinically significant consistent changes in laboratory parameters are rarely observed. However, severe hyperlipidaemia following PUVA treatment for acute skin GVHD has been reported.<sup>206</sup>

Other rare acute side effects of PUVA include bullous pemphigoid,<sup>207-209</sup> lichen planus,<sup>210</sup> lichen planus pemphigoides,<sup>211</sup> polymyositis,<sup>212</sup> influenza-like symptoms,<sup>213</sup> lymphomatoid papulosis in a patient with mycosis fungoides<sup>214</sup> and neurological disorders such as insomnia, nervousness, headache, migraine, dysomnia, depression and dizziness.<sup>215,216</sup> The development of hypertrichosis, acne-like eruptions, milia and seborrhoeic-like facial dermatitis can also uncommonly occur and these changes are usually reversible on stopping treatment.<sup>159,217</sup> An intertriginous, asymptomatic, self-resolving, maculo-papular rash was reported in 8% of subjects undergoing 5-MOP PUVA and this resolved spontaneously despite continuation of PUVA.<sup>160</sup> In one report three patients with mycosis fungoides developed new lesions at sites previously considered to be clear, early in the PUVA course. This might have been due to unmasking of sub-clinical lesions due to inflammation.<sup>218</sup>

**Key points:**

**Relatively common acute adverse effects of PUVA**

- Erythema
- Pruritus
- Nausea
- Polymorphic light eruption

**Uncommon but important acute adverse effects of PUVA**

- PUVA pain
- Idiosyncratic hepatitis
- Psoralen allergy



## 10.2 Long term [Refer to online journal for full discussion].

### 10.2.1 PUVA induced skin cancer

PUVA photochemotherapy is mutagenic,<sup>219-221</sup> carcinogenic<sup>222,223</sup> and immunosuppressive.<sup>224-228</sup> Skin cancer is a well-recognized side effect of PUVA and it is well established that the risk of squamous cell carcinoma (SCC) increases in a dose-dependent manner.<sup>229-234</sup> Additional risk factors include exposure to co-carcinogenic therapeutic agents such as UVB therapy,<sup>235</sup> methotrexate,<sup>236,237</sup> ciclosporin<sup>238</sup> and X-ray radiation/arsenic.<sup>239-242</sup> The human papilloma virus (HPV) has also been suggested as a co-carcinogen and has been detected in PUVA-associated non-melanoma skin cancers (NMSCs), especially types associated with epidermodysplasia verruciformis, particularly types 5, 14 and 20.<sup>243-246</sup> More recently, the USA 16-centre, follow-up study has reported an increased incidence of melanoma in patients treated with PUVA,<sup>247,248</sup> but it remains uncertain that this was a causative association and this association has not been reported by other groups.<sup>233,241,249,250</sup> There is no evidence of either increased incidence of NMSC or melanoma in patients with psoriasis treated by topical PUVA.<sup>251,252</sup> However, the number of patients with high PUVA exposure was low in these studies and many were treated with bath trimethylpsoralen PUVA. It seems likely that any differential risk of carcinogenicity relates more to differences in psoralens than different routes of administration, so it seems reasonable on the basis of current knowledge to believe that the risks per phototoxic exposure should be the same for oral 8-MOP PUVA as for bath 8-MOP PUVA.<sup>251</sup> This is a reason why the (mainly historical) use of cumulative UVA dose with PUVA when considering action limits is less useful than considering number of treatments as cumulative UVA dose will always tend to be less with topical PUVA even when the number of phototoxic exposures is the same.

#### a. PUVA and NMSC

The two studies of most value in assessing NMSC risks in humans treated with PUVA were a North American study and a large Swedish study.<sup>231,232,249</sup> The North American study involved use of maintenance PUVA, and only for one indication (that of psoriasis) in a fashion rarely used in Europe; the Swedish study used PUVA with a methodology close to that which is used in Europe and for a wide variety of indications. The North American study demonstrated that patients receiving more than 200 treatments have about 30 times the risk of developing a new NMSC per year than the general population.<sup>231</sup> An almost identical risk was found in the highest risk group (men who had received 200 or more PUVA treatments) in the Swedish study.<sup>232</sup> The relative risk amongst the highest-risk patients in the Swedish study of 30.7 meant 10 of 180 patients.<sup>232</sup> A meta-analysis reported that the incidence of SCC among patients exposed to high-dose PUVA was 14-fold higher than among patients with low-dose exposure.<sup>253</sup> The risk of skin cancer is persistent despite discontinuation of PUVA.<sup>254</sup> Other risk factors for patients developing NMSC include being of lighter skin phototypes,<sup>255</sup> having skin tumours prior to PUVA and age at starting PUVA,<sup>233</sup> the presence of PUVA keratoses<sup>256</sup> and lentigines.<sup>234,257</sup>

PUVA-associated NMSCs show a reversal of the normal ratio of SCC to basal cell carcinoma (BCC) with a marked increase in SCC and these occur in relatively non-sun-exposed sites.<sup>237</sup> Genital SCC in males treated with PUVA has been reported to be substantially increased (95.7 times that of the general population),<sup>258,259</sup> however, a lower incidence was reported in the Swedish study.<sup>232</sup> [A retrospective study from France of a](#)

cancer registry over 20 years identified only one case of genital SCC in someone with a history of intensive PUVA, out of 48 cases of genital SCC. In addition, there were no reported cases of genital SCC from 5,400 patients who had received PUVA, despite lack of genital protection during PUVA exposures.<sup>260</sup> Despite reports that SCC occurring in patients receiving PUVA are usually well differentiated and non-aggressive,<sup>231,233,242,255</sup> these tumours can rarely metastasize.<sup>237</sup>

Lim *et al.* found high levels of UVB exposure (at least 300 treatments) to be associated with a modest but significant increase in SCC (x1.37) and BCC (x1.45) in the USA PUVA cohort.<sup>235</sup> High level of exposure to methotrexate (total of 4 or more years of use) has also been found to be a significant independent risk factor in the latter cohort, with a relative risk of 2.1 for high versus low, or no exposure.<sup>237</sup> Previously, a synergistic carcinogenic potential between methotrexate and PUVA had been suggested.<sup>236</sup> Data also from the USA cohort showed that the risk of SCC in ciclosporin users was about three times higher than in patients who never used ciclosporin.<sup>238</sup> PUVA patients who have previously received arsenic or X-ray therapy have an increased incidence of skin cancer compared with those who have not had such therapy.<sup>239,241,242</sup>

#### **b. Melanoma**

Patients who receive high doses of PUVA often develop lentigines which can show cytologically atypical melanocytes.<sup>261</sup> A five-fold increase in annual incidence of malignant melanoma in the 16-centre PUVA cohort study, using PUVA to treat psoriasis, was initially reported in 1997.<sup>247</sup> Further follow-up showed a nine-fold increase.<sup>248</sup> Melanoma developed after 15 years and was more common in patients of skin types I/II and who had received at least 250 exposures. There have been a number of case reports of melanoma occurring following PUVA,<sup>262-270</sup> but an increased incidence of melanoma has not been observed in European follow-up studies.<sup>233,241,250,271</sup> So, while there is no doubt that an association between PUVA and melanoma was detected in this one study it is uncertain that PUVA causes melanoma. The association could have been because PUVA, as used in that study, did cause melanoma but equally the association could have been because of confounding (psoriasis patients responsive to PUVA seeking sunlight exposure, for example) or have been due to ascertainment bias (melanomas, and many were early melanomas some of which might not have progressed, more likely to be diagnosed in a prospectively followed group than in the general population).<sup>272</sup> When it was first reported, the potential risk of melanoma induced by PUVA raised questions as to whether PUVA should be contraindicated in those with a history of more than 200 PUVA treatments or those with a personal or family history of melanoma.<sup>271,273</sup>

#### **c. Non-cutaneous cancer risk**

As PUVA alters immune function, especially the lymphocyte, there has been continued concern for the potential development of cancer particularly lymphoma with long-term use of this therapy. This is particularly relevant in psoriasis patients as an association with internal cancer has been found in large cohort studies,<sup>274,275</sup> which includes tumours of oral and pharynx, lung, liver, pancreas, liver, bladder and lymphoma.<sup>276-278</sup> However, previous studies have not demonstrated a consistent increase in cancer risk in the CNS,<sup>279</sup> thyroid,<sup>279</sup> respiratory, pancreas and kidney.<sup>232,249</sup>

Though there are several case reports of leukaemia developing during PUVA therapy.<sup>280-283</sup> Stern *et al.* reported no increase of lymphoma or leukaemia in his PUVA cohort in either 1988 or 1997,<sup>231,247</sup> however, more recent analysis has found the incidence of lymphoma to be increased in this group in those exposed to high levels of methotrexate (RR 4.39), i.e. 36 months of treatment or longer, but not in those exposed to low levels.<sup>284</sup> A study from Finland showed a 2.2-fold increase in non-Hodgkin's lymphoma in patients hospitalized for psoriasis.<sup>277</sup>

#### d. Non-cancerous chronic cutaneous side effects of PUVA

**Keratosis:** these are typically localized to non-sun-exposed skin and risk factors for their development include increased age, male sex and high cumulative UVA dose.<sup>256</sup> They are reported to occur in 46% of patients receiving high-dose (more than 2000 J/cm<sup>2</sup>) PUVA and show cytological atypia.<sup>234</sup> Disseminated superficial actinic porokeratosis has been reported in association with both oral and topical PUVA.<sup>285-288</sup>

**Lentiginos:** PUVA-induced lentiginos are distinct irregular, stellate, darkly pigmented macular lesions and may show cytological atypia.<sup>257,261</sup> Incidence varies from 10% to 53%,<sup>257,289-292</sup> occurring most frequently in those patients exposed to high doses of PUVA<sup>234,257,291</sup> and those of skin type I/II.<sup>289</sup>

**Dyspigmentation:** PUVA-induced mottling consists of hyper- and hypopigmentation associated with atrophy which is mainly localized to areas of overdose.<sup>159,293</sup> Hyperpigmentation has been reported at the lesional sites of patients where calcipotriol ointment has been applied during bath PUVA.<sup>201</sup> Transient hyperpigmentation has also been reported around psoriatic plaques in patients treated with calcipotriol ointment and PUVA.<sup>200</sup> Acquired dermal melanocytosis typically affecting the back of Japanese patients treated with PUVA has been reported.<sup>294,295</sup>

**Photoageing:** PUVA can result in dose-related premature ageing of the skin manifesting as wrinkling, xerosis, loss of elasticity, freckling, telangiectasia, mottled pigmentation, yellowing of the skin and comedones. More marked changes are seen in those of skin type I/II. Both epidermal and dermal changes have been reported with chronic PUVA exposure, including skin atrophy,<sup>296</sup> focal epidermal<sup>297</sup> and elastosis.

**Cataracts:** Free 8-MOP can be detected in human lenses for at least 12 hours after 8-MOP dosing.<sup>298</sup> Previous guidelines from the British Photodermatology Group recommend that protective eyewear be worn for 12 to 24 hours following PUVA and for 24 hours in high-risk individuals, e.g. patients with atopic eczema, children or those with pre-existing cataracts.<sup>299</sup> Previous clinical studies (involving patients advised on eye protection), including the 16-centre prospective cohort study of USA psoriasis patients,<sup>300-302</sup> have not detected an association between the use of PUVA and cataract development. A follow-up study of 82 patients who declined to wear UVA blocking sunglasses after PUVA treatments over 2 to 4 years found no evidence of the development of cataracts.<sup>303</sup>

#### Key points:

##### PUVA is associated with:

- a significant dose-dependent risk of squamous cell carcinoma.
- PUVA keratosis, pigmentary changes, and photoageing

##### PUVA has not been consistently shown to be associated with:

- melanoma
- internal malignancy

### 10.3 How do we identify those who are susceptible to PUVA side effects?

Careful patient selection is essential to prevent side effects, particularly skin cancer (see box below). PUVA should be used with care (generally only if the alternatives are treatments carrying greater risks, such as systemic immunosuppressives) in children due to the risk of causing UV cutaneous damage at a young age.

There is concern that PUVA therapy may lead to worsening of human immunodeficiency virus (HIV) status or may increase risk of skin cancer in people with HIV,<sup>304-306</sup> particularly as SCC and melanoma have been reported to be more aggressive in HIV disease.<sup>307,308</sup> The risk of Merkel cell carcinoma of the skin was increased in the USA PUVA cohort<sup>309</sup> by 100 times, and is also increased in HIV patients.<sup>310</sup> However, studies to date of PUVA use in HIV-infected patients have not demonstrated a deterioration in HIV status or immune function,<sup>311-313</sup> and it has been suggested that in fact, PUVA might be preferable to UVB therapy in those patients infected with HIV.<sup>314</sup>

Patients who are at risk of ocular toxicity are those with pre-existing cataracts, patients who have AD or who are aphakic.

#### RISK FACTORS ASSOCIATED WITH PUVA-INDUCED SKIN CANCER

##### History

- Sun-reactive skin phototype I/II
- Previous history of skin cancer
- Personal/family history of skin cancer or dysplastic naevus syndrome
- Previous exposure to ionizing radiation, arsenic, excessive sunbed exposure
- History of xeroderma pigmentosum or other genetic disorders associated with skin cancer
- Patients on immunosuppressive drug therapy
- HIV disease

##### Examination

- Multiple freckles/moles
- Dysplastic naevi/solar keratoses/SCC *in situ* (Bowen's disease)
- Solar elastosis
- Skin cancer

#### 10.4 How can side effects be prevented in patients receiving PUVA therapy?

Important measures to reduce skin cancer risk include the shielding of high-risk areas on the genitalia and face, education of patients regarding sun protective measures with sunscreen use and protective clothing, and monitoring for pre-malignant or malignant skin lesions. Patients who have received more than 150 to 200 PUVA treatments should be offered an annual skin examination to ensure no pre-malignant or malignant skin lesions have developed,<sup>159,299</sup> and as a component to education of patients and their primary care doctors that they might be at increased risk of skin cancer as a result of medical treatment. Patients should be advised to wear protective UVA blocking glasses from the time they ingest psoralen until 12 hours following PUVA therapy and 24 hours for high-risk individuals, e.g. patients with atopic eczema, children or those with pre-existing cataracts. Sunglasses or opaque UV protective glasses should be used<sup>315,316</sup> and these can be tested for suitability.<sup>315,317</sup> Uncoloured glasses are, if there are any uncertainties about their ability to stop UVA transmission, more suitable than tinted glasses as the latter result in dilation of the pupil potentially allowing more UVA to reach the lens.<sup>318</sup> Protective eyewear should be of sufficient size to reduce peripheral UV exposure and additional side protection is recommended. Most contact lenses have little or no UVA protection and are not recommended.<sup>319</sup>

UVA-blocking goggles should be worn during PUVA therapy. As studies have not shown an increased incidence of cataracts, it has been suggested that an examination by an ophthalmologist should usually be considered only if the patient is at increased risk of cataracts,<sup>299</sup> i.e. patients with pre-existing cataracts, who have AD or who are aphakic.

As the risk of PUVA-induced skin cancer is related to the cumulative exposure, attempts should be made to reduce this exposure. This can be done in a number of ways including more efficient dosimetry using less intense PUVA treatment regimens,<sup>320,321</sup> the avoidance of maintenance treatment, following guidelines on action limit numbers of treatment exposures (e.g. 150 to 200 treatments),<sup>299</sup> consideration of periods of breaks from PUVA with rotational therapy<sup>322</sup> and the use of combination therapy with retinoids<sup>323</sup> or topical vitamin D analogues. Retinoids not only increase the efficacy of PUVA but have a skin cancer prophylactic action.<sup>324,325</sup> Concurrent use of PUVA with ciclosporin should be avoided as it can significantly accelerate skin cancer development in patients receiving such treatment.<sup>238</sup> Topical vitamin D analogues and tazarotene have also been used as dose-sparing agents combined with PUVA.<sup>326,327</sup> There may also be a role of potentially safer photosensitisers such as trimethylangelicin.<sup>328</sup> Photochemotherapy using potentially safer wavelengths of radiation, e.g. NB-UVB requires further research.<sup>329,330</sup> Agents which may protect against PUVA-induced photochemical damage, e.g. green tea or *Polypodium leucotomos* extract may decrease long-term carcinogenesis.<sup>331,332</sup>

#### **Recommendation: (Strength of recommendation D; level of evidence 2+)**

- Concurrent use of PUVA with ciclosporin should be avoided. Post-PUVA ciclosporin is associated with increased risks of NMSCs and should be avoided when possible. However, previous use of ciclosporin should not preclude consideration for PUVA.

#### 10.5 How are the side effects managed in patients receiving PUVA therapy?

Pre-malignant and malignant skin lesions are treated in the same way as patients not receiving PUVA. PUVA requires to be discontinued if neoplastic lesions develop and alternative therapy should be considered but ciclosporin should be avoided.<sup>238</sup> Introduction of acitretin can be helpful in management of patients with multiple keratoses and skin cancer following PUVA.<sup>324,325,333</sup> These individuals will require careful follow-up as they are at increased risk of further skin cancers developing with time.

### 10.6 PUVA and pregnancy

As PUVA therapy is mutagenic there is concern regarding potential teratogenicity of this treatment. Oral psoralen is associated with reduced birth rate and teratogenicity in animal studies,<sup>334-336</sup> but this is not found in humans.<sup>337-339</sup> One study observed a marked increase in infants with low birth weights when pregnancy occurred after treatment.<sup>338</sup> It was thought this may be an effect of the underlying disease rather than the treatment itself. Recently, it has been reported that pregnant women with severe psoriasis have a 1.4-fold increased risk of giving birth to infants with low birth weights.<sup>340</sup> It has been suggested that local topical PUVA may be relatively safe in pregnancy as it does not give rise to detectable levels of psoralen.<sup>341</sup> It was recommended that PUVA therapy should be avoided during pregnancy whenever possible as it is mutagenic.<sup>337,342</sup>

There is no evidence that PUVA is a significant teratogen. (**Level of evidence 2++**)

**Recommendation: (Strength of recommendation D; Level of evidence 4)**

- It is recommended that female patients should avoid conception during PUVA therapy and that, if despite this advice pregnancy does occur, PUVA should then be discontinued.

## 11.0 PROTOCOLS AND PRACTICAL CONSIDERATIONS

### 11.1 What is the optimum protocol for the delivery of PUVA therapy to optimize outcome in patients with psoriasis, eczema and PLE?

Examples of treatment schedules commonly used in the UK can be accessed at:

<http://www.bad.org.uk/healthcare-professionals/clinical-services/service-standards/phototherapy>

<http://www.photonet.scot.nhs.uk> [the Scottish national managed clinical network for phototherapy photonet website]

<http://www.phototherapysupport.net> [the south-east of England phototherapy network website]

These may be used as guidance to the phototherapist in determining the optimum protocol.

### 11.2 How should a PUVA therapy clinic be set up, taking account of:

- equipment
- staffing/training
- support (e.g. medical physics, servicing)

- dosimetry/QA
- records/database

A Phototherapy Working Party Report has been produced by the BAD on the minimum standards for phototherapy services, and includes a phototherapy service review toolkit.

<http://www.bad.org.uk/healthcare-professionals/clinical-services/service-standards/phototherapy>

In addition, the BPG has also published guidelines for dosimetry and calibration in ultraviolet radiation therapy.<sup>343</sup> A joint BAD and BPG update of these guidelines is currently in press with the BJD.<sup>344</sup>

<http://www.bpg.org.uk/index.asp?SID=7&PID=13>

<http://www.bad.org.uk/healthcare-professionals/clinical-standards/clinical-guidelines>

## 12.0 PRE-TREATMENT ASSESSMENT

### 12.1 Risk assessment and patient counselling

Prior to phototherapy, a formal risk assessment, which can be made by a nurse or a doctor, should include assessment of skin cancer risk, use of concomitant topical and systemic drugs, drug allergies, photosensitivity, liver or kidney disease and history of cataracts.

- All patients who have had more than 150 to 200 exposures of PUVA should be offered annual assessment for any pre-malignant or malignant skin lesions.
- Advice should be given on eye protection for 12 to 24 hours following oral PUVA, and considered for bath PUVA for widespread dermatoses, and for 24 hours in high-risk individuals, e.g. patients with atopic eczema, children or those with pre-existing cataracts or are aphakic. Eye protection should be worn when outdoors, when exposed to sunlight transmitting through window glass, and if exposed to indoor lighting capable of emitting ultraviolet A (including 'energy saving' compact fluorescent lamps).
- Advice should be given on photoprotection following each PUVA session, especially over the 12 hours after each treatment.
- Informed consent should be taken and appropriate patient information leaflet provided.
- Some examples of patient information leaflets can be viewed on:

<http://www.bad.org.uk/shared/get-file.ashx?itemtype=document&id=1644>

[page 35-38]

<http://www.phototherapysupport.net/view-document.asp?FileID=40> [appendix 2, page 44-49]

<http://www.photonet.scot.nhs.uk/professionals-area/patient-information-sheets/>

### 12.2 Baseline investigations

- In view of the minimal risk of hepatotoxicity, routine liver function tests are unnecessary, but should be performed to establish baseline levels in cases where there is known or suspected pre-existing liver dysfunction.

- There is no definite evidence that lupus can be induced or exacerbated by PUVA. The routine checking of antinuclear antibodies (ANA) is unnecessary, unless there is history of photosensitivity.
- If the patient is at an increased risk of cataracts (e.g. children with atopic eczema), a baseline assessment by an ophthalmologist should be considered.
- The MPD should be established to avoid phototoxicity and also, importantly, to ensure sufficient psoralen in the skin at the correct time.<sup>345</sup>

### 13.0 FUTURE DIRECTIONS

We have presented updated evidence to assist in the safe and effective use of PUVA therapy, although gaps still remain in direct evidence of comparison. Suggested areas for future research include:

- A randomised comparative study, comparing PUVA with biological therapy for chronic plaque psoriasis; this would help guidance on whether to prescribe PUVA before biological therapies, taking into consideration the relative risks and efficacy.
- A study to investigate whether or not there is an effect of MPD measurement at 72 and 96 hours on erythematous episodes during PUVA and efficacy outcome measures.

### 14.0 RECOMMENDED AUDIT POINTS

- (A) Is there a system in place to record and recall episodes of 'burning' which clearly:
- a. grades each episode
  - b. reviews all episodes at 6-monthly intervals
  - c. interprets the result in the context of the total number of treatments and total number of patients treated?
- (B) Over the past 12 months:
1. Was there clear documentation of instances of painful erythema?
  2. Was there clear documentation of staff training records for topical and/or oral PUVA therapy?
  3. Was a patient information leaflet provided to:
    - a. the last 20 consecutive patients receiving topical PUVA therapy?
    - b. the last 50 consecutive patients receiving oral PUVA therapy?
  4. Was there clear documentation on advising patients on the risk of skin carcinogenicity on sun-exposed skin for:
    - a. the last 20 consecutive patients receiving topical PUVA therapy?
    - b. the last 50 consecutive patients receiving oral PUVA therapy?
  5. Was there clear documentation on advising patients on eye protection and UV protection following each oral PUVA treatment for the last 50 consecutive patients?



The audit recommendation of 20 or 50 cases per department is to reduce variation in the results due to a single patient, and allow benchmarking between different units. However, departments unable to achieve this recommendation may choose to audit all cases seen in the preceding 12 months.

## 15.0 SUMMARY

*(See full manuscript for details of evidence)*

Please see summary of recommendations for the safe and effective use of PUVA therapy in particular clinical situations (Table 4).

Psoriasis	All dermatology phototherapy units should offer both PUVA as well as oral PUVA to treat psoriasis. <b>(Strength of recommendation B)</b>
	PUVA should usually be offered before oral systemic therapy for patients with chronic plaque psoriasis that has not responded adequately to other therapies including narrowband UVB. <b>(Strength of recommendation B)</b>
	PUVA should always be considered before biological therapy to treat chronic plaque psoriasis. <b>(Strength of recommendation C)</b>
	<u>Although PUVA may occasionally be appropriate as a first-line phototherapy treatment for especially thick and/or extensive plaque psoriasis it should usually only be considered in patients with chronic plaque psoriasis, if NB-UVB has not been adequately effective.</u> <b>(Strength of recommendation B)</b>
Atopic eczema	PUVA should be considered in patients with atopic eczema only if NB-UVB has not been adequately effective. <b>(Strength of recommendation D)</b>
Cutaneous T cell lymphoma of the mycosis fungoides (MF) type	PUVA is the first line treatment for plaque-stage CTCL. <b>(Strength of recommendation B)</b>
	Maintenance therapy may be considered to prevent relapse in quickly recurrent plaque-stage CTCL. <b>(Strength of recommendation D)</b>
	NB-UVB is as effective as PUVA and is the treatment of choice for patch-stage CTCL. <b>(Strength of recommendation D)</b>
	Combination therapy with PUVA and interferon or retinoids/rexinoids should be considered in the treatment of early stage MF, if the response to monotherapy is slow. <b>(Strength of recommendation B)</b>
Vitiligo	PUVA should only be considered for widespread vitiligo if NB-UVB has been not shown to be adequately effective. <b>(Strength of recommendation A)</b>
Polymorphic light eruption	PUVA should be considered if UVB has failed, or has previously triggered the eruption sufficiently to compromise a course of therapy, or if there are other practical issues. PUVA should be considered before other systemic treatments. <b>(Strength of recommendation D)</b>
Chronic actinic dermatitis (CAD)	In the treatment of CAD, PUVA therapy should be considered in a specialist unit experienced with managing this disease, with full knowledge of the individual patient's action spectrum. Special

	precautions including inpatient supervision, topical/oral corticosteroid cover may be required. ( <b>Strength of recommendation D</b> )
Idiopathic solar urticaria (SU)	In the management of SU (after full assessment including definition of the action spectrum), PUVA can be considered. The treatment should be carried out with full knowledge of the patient's action spectrum, in a specialist unit experienced with managing this disease. ( <b>Strength of recommendation D</b> )
Erythropoietic protoporphyria (EPP)	PUVA is rarely appropriate in EPP, NB-UVB is the phototherapy of first choice. ( <b>Strength of recommendation D</b> )
Actinic prurigo (AP)	NB-UVB may be a safer therapeutic option in terms of phototherapy-associated carcinogenic risk in patients with AP, particularly in children, and should be considered before PUVA. ( <b>Strength of recommendation D</b> )
Hyperkeratotic palmoplantar eczema	Oral PUVA should usually be considered as the first-line PUVA treatment for patients with palmoplantar dermatoses. ( <b>Strength of recommendation D(GPP)</b> )
Palmoplantar psoriasis	PUVA using topical or oral psoralen should be considered as a treatment for palmoplantar psoriasis. ( <b>Strength of recommendation C</b> )
Palmoplantar pustulosis	PUVA using oral psoralen should be considered as a treatment for palmoplantar pustulosis. ( <b>Strength of recommendation C</b> ) Unless there are contraindications, the combination of oral PUVA with oral retinoids should be considered as a treatment for palmoplantar pustulosis. ( <b>Strength of recommendation A</b> )
Pregnancy	It is recommended that female patients should avoid conception during PUVA therapy and that if despite this advice pregnancy does occur, PUVA should be discontinued. ( <b>Strength of recommendation D</b> )

**Table 4.** Recommendations in particular clinical situations

## SUPPORTING INFORMATION

Additional supporting information including the search strategy may be found in the online version of this article.

## ACKNOWLEDGEMENTS

We are very grateful to Professor Alex Anstey (University of Cardiff and Ysbyty Gwynedd), Dr JJ Lloyd (University of Newcastle and Royal Victoria Infirmary) and Ms Trish Garibaldinos (St.John's Institute of Dermatology), as well as everyone who commented on the draft during the consultation period.

**Commented [AE2]:** As now changed and this was not like a study in which all authors and contributors are cited with place of work at time of the study.

## APPENDIX 1

### Levels of evidence

Level of evidence	Type of evidence
1++	High-quality meta-analyses, systematic reviews of RCTs, or RCTs with a very low risk of bias
1+	Well-conducted meta-analyses, systematic reviews of RCTs, or RCTs with a low risk of bias
1-	Meta-analyses, systematic reviews of RCTs, or RCTs with a high risk of bias*
2++	High-quality systematic reviews of case-control or cohort studies High-quality case-control or cohort studies with a very low risk of confounding, bias or chance and a high probability that the relationship is causal
2+	Well-conducted case-control or cohort studies with a low risk of confounding, bias or chance and a moderate probability that the relationship is causal
2-	Case-control or cohort studies with a high risk of confounding, bias or chance and a significant risk that the relationship is not causal*
3	Non-analytical studies (for example, case reports, case series)
4	Expert opinion, formal consensus

\*Studies with a level of evidence '-' should not be used as a basis for making a recommendation.

### Strength of recommendation

Class	Evidence
A	<ul style="list-style-type: none"> <li>At least one meta-analysis, systematic review, or RCT rated as 1++, and directly applicable to the target population, <b>or</b></li> <li>A systematic review of RCTs or a body of evidence consisting principally of studies rated as 1+, directly applicable to the target population and demonstrating overall consistency of results</li> <li>Evidence drawn from a NICE technology appraisal</li> </ul>
B	<ul style="list-style-type: none"> <li>A body of evidence including studies rated as 2++, directly applicable to the target population and demonstrating overall consistency of results, <b>or</b></li> <li>Extrapolated evidence from studies rated as 1++ or 1+</li> </ul>
C	<ul style="list-style-type: none"> <li>A body of evidence including studies rated as 2+, directly applicable to the target population and demonstrating overall consistency of results, <b>or</b></li> <li>Extrapolated evidence from studies rated as 2++</li> </ul>
D	<ul style="list-style-type: none"> <li>Evidence level 3 or 4, <b>or</b></li> <li>Extrapolated evidence from studies rated as 2+, <b>or</b></li> <li>Formal consensus</li> </ul>
D (GPP)	<ul style="list-style-type: none"> <li>A good practice point (GPP) is a recommendation for best practice based on the experience of the guideline development group</li> </ul>

RCT: randomised controlled trial; NICE: National Institute for Health and Clinical Excellence.


<b>Advantages of oral PUVA</b>	<b>Advantages of topical PUVA</b>
Shorter overall outpatient attendance times	No risk of gastrointestinal adverse effects
Less staff involvement	Drug interactions unlikely
Less risk of phototoxic reactions from natural UV exposure (lower concentration of psoralen in the skin after treatment)	Eye protection not <u>always</u> required
Only practical option for whole-body treatment for units with inadequate bath facilities	Shorter periods in treatment cubicle due to smaller dose of UVA

1st author	Publication year	Bath psoralen	Oral psoralen	UVA regimen	Randomised ?	Blinded?	Proportion (percentage) cleared with oral PUVA	Proportion (percentage) cleared with bath PUVA	Difference (% more clearing with oral PUVA); 95% CI for difference
Turjanmaa <sup>12</sup>	1985	TMP 3 mg/l	8-MOP 0.6 mg/Kg	arbitrary starting doses; 3 times a week; incremental regimen not reported	No	No	37/43 (86%)	42/50 (84%)	2%; -12% to 17%
Lowe <sup>13</sup>	1986	3.75 mg/l	8-MOP 0.6 mg/Kg	Skin phototype based starting dose and incremental regimen	No	No	8/20 (40%)	8/20 (40%)	0%; -30% to 30%
Collins <sup>10</sup>	1992	8-MOP 3.78 mg/l	8-MOP 0.6 mg/Kg	skin phototype based starting doses; 3 times a week; no > 20 treatments	Yes (but allocation not concealed)	No	14/22 (64%)	14/22 (64%)	0%; -28% to 28%
Cooper <sup>11</sup>	2000	8-MOP 2.6 mg/l	8-MOP 0.6 mg/Kg	70% MPD starting dose; 2 times a week; percentage based incremental regimen	Yes (but allocation not concealed)	No	14/17 (82%)	17/17 (100%)	-18%; -36% to 0.5%


**Table 2.** Controlled studies comparing whole-body topical PUVA ('bath PUVA') with oral PUVA

Phototherapy type	Rash provocation	Erythema	Pruritus	Herpes simplex
PUVA	12-50%	8-67%	18-33%	--
NB-UVB	62%	54%	15%	--
BB-UVB	53%	27%	40%	20%

**Table 3.** Incidence of side effects with different phototherapy




**Figure 1.** Controlled study (including RCTs by Collins *et al.* and Cooper *et al.*) comparisons of oral PUVA with bath PUVA for psoriasis




**Figure 2.** RCT comparing PUVA with placebo for psoriasis







**Figure 3.** RCTs comparing conventional systemic therapies with placebo for psoriasis




**Figure 4.** Retrospective comparison of PUVA (n = 118 patients) with biologicals, Inzinger *et al.*<sup>7</sup> Baseline mean PASI for PUVA was 15 and for biologicals was 16.9. Outcome of PASI 75% reduction.



**Figure 5.** Retrospective comparison of PUVA (n = 118 patients) with biologicals, Inzinger *et al.*<sup>7</sup> Baseline mean PASI for PUVA was 15 and for biologicals was 16.9. Outcome of **PASI 90%** reduction (similar outcome measure to 'clearance' or 'minimal residual activity').



**Figure 6.** Controlled studies comparing PUVA with narrowband UVB for psoriasis



**Figure 7** Controlled studies comparing PUVA with narrowband UVB for vitiligo

## REFERENCES

- 1 Bell HK, Ormerod AD. Writing a British Association of Dermatologists clinical guideline: an update on the process and guidance for authors. *Br J Dermatol* 2009; **160**:725-8.
- 2 Brouwers MC, Kho ME, Browman GP *et al.* AGREE II: advancing guideline development, reporting and evaluation in health care. *Can Med Assoc J* 2010; **182**:E839-42.
- 3 Neyeloff JL, Fuchs SC, Moreira LB. Meta-analyses and Forest plots using a microsoft excel spreadsheet: step-by-step guide focusing on descriptive data analysis. *BMC Res Notes* 2012; **5**:52.
- 4 Hönigsmann H. History of phototherapy in dermatology. *Photochem Photobiol Sci* 2013; **12**:16-21.
- 5 Dawe RS. A quantitative review of studies comparing the efficacy of narrow-band and broad-band ultraviolet B for psoriasis. *Br J Dermatol* 2003; **149**:669-72.
- 6 Yones SS, Palmer RA, Garibaldinos TM *et al.* Randomized double-blind trial of treatment of vitiligo: Efficacy of psoralen-UV-A therapy vs narrowband-UV-B therapy. *Arch Dermatol* 2007; **143**:578-84.
- 7 Inzinger M, Heschl B, Weger W *et al.* Efficacy of psoralen plus ultraviolet A therapy vs. biologics in moderate to severe chronic plaque psoriasis: retrospective data analysis of a patient registry. *Br J Dermatol* 2011; **165**:640-5.
- 8 Sakuntabhai A, Matthews JN, Farr PM. Improved prediction of the minimal phototoxic dose in PUVA therapy. *Br J Dermatol* 1994; **130**:604-9.
- 9 Gemmeke A, Schonlebe J, Koch A *et al.* Pityriasis rubra pilaris--a retrospective single center analysis over eight years. *J Dtsch Dermatol Ges* 2010; **8**:439-44.
- 10 Collins P, Rogers S. Bath-water compared with oral delivery of 8-methoxypsoralen PUVA therapy for chronic plaque psoriasis. *Br J Dermatol* 1992; **127**:392-5.
- 11 Cooper EJ, Herd RM, Priestley GC *et al.* A comparison of bathwater and oral delivery of 8-methoxypsoralen in PUVA therapy for plaque psoriasis. *Clin Exp Dermatol* 2000; **25**:111-4.
- 12 Turjanmaa K, Salo H, Reunala T. Comparison of trioxsalen bath and oral methoxsalen PUVA in psoriasis. *Acta Derm Venereol* 1985; **65**:86-8.
- 13 Lowe NJ, Weingarten D, Bourget T *et al.* PUVA therapy for psoriasis: comparison of oral and bath-water delivery of 8-methoxypsoralen. *J Am Acad Dermatol* 1986; **14**:754-60.
- 14 Berneburg M, Herzinger T, Rumpf J *et al.* Efficacy of bath psoralen plus ultraviolet A (PUVA) vs. system PUVA in psoriasis: a prospective, open, randomized, multicentre study. *Br J Dermatol* 2013; **169**:704-8.
- 15 Alshiyab D, Chin MF, Edwards C *et al.* An evaluation of the preferences of patients with psoriasis between systemic psoralen plus ultraviolet A and bath psoralen plus ultraviolet A. *Br J Dermatol* 2015; **172**:1457-8.
- 16 Sivanesan SP, Gattu S, Hong J *et al.* Randomized, double-blind, placebo-controlled evaluation of the efficacy of oral psoralen plus ultraviolet A for the treatment of plaque-type psoriasis using the Psoriasis Area Severity Index score (improvement of 75% or greater) at 12 weeks. *J Am Acad Dermatol* 2009; **61**:793-8.
- 17 Nugteren-Huying WM, van der Schroeff JG, Hermans J *et al.* Fumaric acid therapy for psoriasis: a randomized, double-blind, placebo-controlled study. *J Am Acad Dermatol* 1990; **22**:311-2.
- 18 Ellis CN, Fradin MS, Messana JM *et al.* Cyclosporine for plaque-type psoriasis. Results of a multidose, double-blind trial. *N Engl J Med* 1991; **324**:277-84.
- 19 Saurat JH, Stingl G, Dubertret L *et al.* Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION). *Br J Dermatol* 2008; **158**:558-66.
- 20 Kuitunen T, Malmstrom J, Palva E *et al.* Pancytopenia induced by low-dose methotrexate. A study of the cases reported to the Finnish Adverse Drug Reaction Register From 1991 to 1999. *Scand J Rheumatol* 2005; **34**:238-41.

- 21 Souto A, Maneiro JR, Salgado E *et al.* Risk of tuberculosis in patients with chronic immune-mediated inflammatory diseases treated with biologics and tofacitinib: a systematic review and meta-analysis of randomized controlled trials and long-term extension studies. *Rheumatology (Oxford)* 2014; **53**:1872-85.
- 22 Smith CH, Anstey AV, Barker JN *et al.* British Association of Dermatologists' guidelines for biologic interventions for psoriasis 2009. *Br J Dermatol* 2009; **161**:987-1019.
- 23 *British National Formulary (BNF)* 69. London: BMJ Publishing Group Ltd and Royal Pharmaceutical Society. 2015.
- 24 Van Weelden H, Baart de la Faille H, Young E *et al.* Comparison of narrow-band UV-B phototherapy and PUVA photochemotherapy in the treatment of psoriasis. *Acta Derm Venereol* 1990; **70**:212-5.
- 25 Tanew A, Radakovic-Fijan S, Schemper M *et al.* Narrowband UV-B phototherapy vs photochemotherapy in the treatment of chronic plaque-type psoriasis: a paired comparison study. *Arch Dermatol* 1999; **135**:519-24.
- 26 Gordon PM, Diffey BL, Matthews JN *et al.* A randomized comparison of narrow-band TL-01 phototherapy and PUVA photochemotherapy for psoriasis. *J Am Acad Dermatol* 1999; **41**:728-32.
- 27 Dawe RS, Cameron H, Yule S *et al.* A randomized controlled trial of narrowband ultraviolet B vs bath-psoralen plus ultraviolet A photochemotherapy for psoriasis. *Br J Dermatol* 2003; **148**:1194-204.
- 28 Markham T, Rogers S, Collins P. Narrowband UV-B (TL-01) phototherapy vs oral 8-methoxypsoralen psoralen-UV-A for the treatment of chronic plaque psoriasis. *Arch Dermatol* 2003; **139**:325-8.
- 29 Snellman E, Klimenko T, Rantanen T. Randomized half-side comparison of narrowband UVB and trimethylpsoralen bath plus UVA treatments for psoriasis. *Acta Derm Venereol* 2004; **84**:132-7.
- 30 Yones SS, Palmer RA, Garibaldinos TT *et al.* Randomized double-blind trial of the treatment of chronic plaque psoriasis: efficacy of psoralen-UV-A therapy vs narrowband UV-B therapy. *Arch Dermatol* 2006; **142**:836-42.
- 31 Salem SA, Barakat MA, Morcos CM. Bath psoralen+ultraviolet A photochemotherapy vs. narrow band-ultraviolet B in psoriasis: a comparison of clinical outcome and effect on circulating T-helper and T-suppressor/cytotoxic cells. *Photodermatol Photoimmunol Photomed* 2010; **26**:235-42.
- 32 Dayal S, Mayanka, Jain VK. Comparative evaluation of NBUVB phototherapy and PUVA photochemotherapy in chronic plaque psoriasis. *Indian J Dermatol Venereol Leprol* 2010; **76**:533-7.
- 33 Chauhan PS, Kaur I, Dogra S *et al.* Narrowband ultraviolet B versus psoralen plus ultraviolet A therapy for severe plaque psoriasis: an Indian perspective. *Clin Exp Dermatol* 2011; **36**:169-73.
- 34 Cameron H, Dawe RS, Yule S *et al.* A randomized, observer-blinded trial of twice vs. three times weekly narrowband ultraviolet B phototherapy for chronic plaque psoriasis. *Br J Dermatol* 2002; **147**:973-8.
- 35 de Jager MEA, de Jong EMGJ, van de Kerkhof PCM *et al.* Efficacy and safety of treatments for childhood psoriasis: A systematic literature review. *J Am Acad Dermatol* 2010; **62**:1013-30.
- 36 Uetsu N, Horio T. Treatment of persistent severe atopic dermatitis in 113 Japanese patients with oral psoralen photo-chemotherapy. *J Dermatol* 2003; **30**:450-7.
- 37 Hannuksela M, Karvonen J, Husa M *et al.* Ultraviolet light therapy in atopic dermatitis. *Acta Derm Venereol Suppl* 1985; **114**:137-9.
- 38 Tzaneva S, Kittler H, Holzer G *et al.* 5-Methoxypsoralen plus ultraviolet (UV) A is superior to medium-dose UVA1 in the treatment of severe atopic dermatitis: a randomized crossover trial. *Br J Dermatol* 2010; **162**:655-60.
- 39 Garritsen FM, Brouwer MW, Limpens J *et al.* Photo(chemo)therapy in the management of atopic dermatitis: an updated systematic review with implications for practice and research. *Br J Dermatol* 2014; **170**:501-13.

- 40 Der Petrossian M, Seeber A, Hönigsmann H *et al.* Half-side comparison study on the efficacy of 8-methoxypsoralen bath- PUVA versus narrow-band ultraviolet B phototherapy in patients with severe chronic atopic dermatitis. *Br J Dermatol* 2000; **142**:39-43.
- 41 de Kort WJ, van Weelden H. Bath psoralen-ultraviolet A therapy in atopic eczema. *J Eur Acad Dermatol Venereol* 2000; **14**:172-4.
- 42 Sheehan MP, Atherton DJ, Norris P *et al.* Oral psoralen photochemotherapy in severe childhood atopic eczema: an update. *Br J Dermatol* 1993; **129**:431-6.
- 43 Clayton TH, Clark SM, Turner D *et al.* The treatment of severe atopic dermatitis in childhood with narrowband ultraviolet B phototherapy. *Clin Exp Dermatol* 2007; **32**:28-33.
- 44 Roenigk HH. Photochemotherapy for mycosis fungoides. *Arch Dermatol* 1977; **113**:1047-51.
- 45 Cox NH, Turbitt ML, Ashworth J *et al.* Distribution of T cell subsets and Langerhans cells in mycosis fungoides, and the effect of PUVA therapy. *Clin Exp Dermatol* 1986; **11**:564-8.
- 46 Okamoto H, Takigawa M, Horio T. Alteration of lymphocyte functions by 8-methoxypsoralen and longwave ultraviolet radiation. I. Suppressive effects of PUVA on T-lymphocyte migration in vitro. *J Invest Dermatol* 1985; **84**:203-5.
- 47 Gilchrist BA. Methoxsalen photochemotherapy for mycosis fungoides. *Cancer Treat Rep* 1979; **63**:663-7.
- 48 Gasparro FP, Dall'Amico R, O'Malley M *et al.* Cell membrane DNA: a new target for psoralen photoadduct formation. *Photochem Photobiol* 1990; **52**:315-21.
- 49 Ramsay DL, Lish KM, Yalowitz CB *et al.* Ultraviolet-B phototherapy for early-stage cutaneous T-cell lymphoma. *Arch Dermatol* 1992; **128**:931-3.
- 50 Resnik KS, Vonderheid EC. Home UV phototherapy of early mycosis fungoides: long-term follow-up observations in thirty-one patients. *J Am Acad Dermatol* 1993; **29**:73-7.
- 51 Plettenberg H, Stege H, Megahed M *et al.* Ultraviolet A1 (340-400 nm) phototherapy for cutaneous T-cell lymphoma. *J Am Acad Dermatol* 1999; **41**:47-50.
- 52 Zane C, Leali C, Airo P *et al.* "High-dose" UVA1 therapy of widespread plaque-type, nodular, and erythrodermic mycosis fungoides. *J Am Acad Dermatol* 2001; **44**:629-33.
- 53 Pothiwala SZ, Baldwin BT, Cherpelis BS *et al.* The role of phototherapy in cutaneous T-cell lymphoma. *J Drugs Dermatol* 2010; **9**:764-72.
- 54 Whittaker SJ. personal communication. 2015.
- 55 Whittaker SJ, Marsden JR, Spittle M *et al.* Joint British Association of Dermatologists and U.K. Cutaneous Lymphoma Group guidelines for the management of primary cutaneous T- cell lymphomas. *Br J Dermatol* 2003; **149**:1095-107.
- 56 Carter J, Zug KA. Phototherapy for cutaneous T-cell lymphoma: online survey and literature review. *J Am Acad Dermatol* 2009; **60**:39-50.
- 57 Westerhof W, Nieuweboer Krobotova L. Treatment of vitiligo with UV-B radiation vs topical psoralen plus UV- A. *Arch Dermatol* 1997; **133**:1525-8.
- 58 Bhatnagar A, Kanwar AJ, Parsad D *et al.* Comparison of systemic PUVA and NB-UVB in the treatment of vitiligo: An open prospective study. *J Eur Acad Dermatol Venereol* 2007; **21**:638-42.
- 59 Bhatnagar A, Kanwar AJ, Parsad D *et al.* Psoralen and ultraviolet A and narrow-band ultraviolet B in inducing stability in vitiligo, assessed by vitiligo disease activity score: An open prospective comparative study. *J Eur Acad Dermatol Venereol* 2007; **21**:1381-5.
- 60 Man I, Dawe RS, Ferguson J. Artificial hardening for polymorphic light eruption: practical points from ten years' experience. *Photodermatol Photoimmunol Photomed* 1999; **15**:3-4.
- 61 Mastalier U, Kerl H, Wolf P. Clinical, laboratory, phototest and phototherapy findings in polymorphic light eruptions: a retrospective study of 133 patients. *Eur J Dermatol* 1998; **8**:554-9.



- 62 Berg M, Ros AM, Berne B. Ultraviolet A phototherapy and trimethylpsoralen UVA photochemotherapy in polymorphous light eruption--a controlled study. *Photodermatol Photoimmunol Photomed* 1994; **10**:139-43.
- 63 Bilisland D, George SA, Gibbs NK *et al.* A comparison of narrow band phototherapy (TL-01) and photochemotherapy (PUVA) in the management of polymorphic light eruption. *Br J Dermatol* 1993; **129**:708-12.
- 64 Leonard F, Morel M, Kalis B *et al.* Psoralen plus ultraviolet A in the prophylactic treatment of benign summer light eruption. *Photodermatol Photoimmunol Photomed* 1991; **8**:95-8.
- 65 Murphy GM, Logan RA, Lovell CR *et al.* Prophylactic PUVA and UVB therapy in polymorphic light eruption--a controlled trial. *Br J Dermatol* 1987; **116**:531-8.
- 66 Addo HA, Sharma SC. UVB phototherapy and photochemotherapy (PUVA) in the treatment of polymorphic light eruption and solar urticaria. *Br J Dermatol* 1987; **116**:539-47.
- 67 Molin L, Volden G. Treatment of polymorphous light eruption with PUVA and prednisolone. *Photo-dermatology* 1987; **4**:107-8.
- 68 Ortel B, Tanew A, Wolff K *et al.* Polymorphous light eruption: action spectrum and photoprotection. *J Am Acad Dermatol* 1986; **14**:748-53.
- 69 Jansén CT, Karvonen J, Malmiharju T. PUVA therapy for polymorphous light eruptions: Comparison of systemic methoxsalen and topical trioxsalen regimens and evaluation of local protective mechanisms. *Acta Derm Venereol* 1982; **62**:317-20.
- 70 Parrish JA, Le Vine MJ, Morison WL *et al.* Comparison of PUVA and beta-carotene in the treatment of polymorphous light eruption. *Br J Dermatol* 1979; **100**:187-91.
- 71 Gschnait F, Hönigsmann H, Brenner W *et al.* Induction of UV light tolerance by PUVA in patients with polymorphous light eruption. *Br J Dermatol* 1978; **99**:293-5.
- 72 Patel GK, Harding KG, Millis CM. Severe disabling Koebnerizing ulcerated necrobiosis lipoidica successfully managed with topical PUVA (18). *Br J Dermatol* 2000; **143**:668-9.
- 73 Norris PG, Hawk JL. Successful treatment of severe polymorphous light eruption with azathioprine. *Arch Dermatol* 1989; **125**:1377-9.
- 74 Shipley DR, Hewitt JB. Polymorphic light eruption treated with cyclosporin. *Br J Dermatol* 2001; **144**:446-7.
- 75 Murphy GM, McCann P, O'Leary A *et al.* Guidelines for the use of phototherapy and photochemotherapy in Ireland. *Ir J Med Sci* 1997; **166**:92-7.
- 76 Corbett MF, Hawk JL, Herxheimer A *et al.* Controlled therapeutic trials in polymorphic light eruption. *Br J Dermatol* 1982; **107**:571-81.
- 77 Jansén CT. Beta-carotene treatment of polymorphous light eruptions. *Dermatologica* 1974; **149**:363-73.
- 78 Mathews-Roth MM, Pathak MA, Fitzpatrick TB *et al.* Beta carotene therapy for erythropoietic protoporphyria and other photosensitivity diseases. *Arch Dermatol* 1977; **113**:1229-32.
- 79 Jansén CT. Oral carotenoid treatment in polymorphous light eruption: a cross-over comparison with oxychloroquine and placebo. *Photodermatol* 1985; **2**:166-9.
- 80 Neumann R, Rappold E, Pohl-Markl H. Treatment of polymorphous light eruption with nicotinamide: a pilot study. *Br J Dermatol* 1986; **115**:77-80.
- 81 Ortel B, Wechdorn D, Tanew A *et al.* Effect of nicotinamide on the phototest reaction in polymorphous light eruption. *Br J Dermatol* 1988; **118**:669-73.
- 82 Rhodes LE, Durham BH, Fraser WD *et al.* Dietary fish oil reduces basal and ultraviolet B-generated PGE2 levels in skin and increases the threshold to provocation of polymorphic light eruption. *J Invest Dermatol* 1995; **105**:532-5.
- 83 Hadshiew I, Stäb F, Untiedt S *et al.* Effects of topically applied antioxidants in experimentally provoked polymorphous light eruption. *Dermatology* 1997; **195**:362-8.
- 84 Rippke F, Wendt G, Bohnsack K *et al.* Results of photoprovocation and field studies on the efficacy of a novel topically applied antioxidant in polymorphous light eruption. *J Dermatolog Treat* 2001; **12**:3-8.

- 85 Eberlein-König B, Fesq H, Abeck D *et al.* Systemic vitamin C and vitamin E do not prevent photoprovoation test reactions in polymorphous light eruption. *Photodermatol Photoimmunol Photomed* 2000; **16**:50-2.
- 86 Przybilla B, Heppeler M, Ruzicka T. Preventive effect of an E. coli-filtrate (Colibiogen) in polymorphous light eruption. *Br J Dermatol* 1989; **121**:229-33.
- 87 Patel DC, Bellanay GJ, Seed PT *et al.* Efficacy of short-course oral prednisolone in polymorphic light eruption: a randomized controlled trial. *Br J Dermatol* 2000; **143**:828-31.
- 88 Marguery MC, Montazeri A, El Sayed F *et al.* Chronic actinic dermatitis: A severe case responding to cyclosporin- bath-PUVA therapy. *J Dermatolog Treat* 1997; **8**:281-3.
- 89 Nousari HC, Anhalt GJ, Morison WL. Mycophenolate in psoralen-UV-A desensitization therapy for chronic actinic dermatitis. *Arch Dermatol* 1999; **135**:1128-9.
- 90 Hindson C, Downey A, Sinclair S *et al.* PUVA therapy of chronic actinic dermatitis: A 5-year follow-up. *Br J Dermatol* 1990; **123**:273.
- 91 Hindson C, Spiro J, Downey A. PUVA therapy of chronic actinic dermatitis. *Br J Dermatol* 1985; **113**:157-60.
- 92 Gardeazábal J, Arregui MA, Gil N *et al.* Successful treatment of musk ketone-induced chronic actinic dermatitis with cyclosporine and PUVA. *J Am Acad Dermatol* 1992; **27**:838-42.
- 93 Burke DA, Corey G, Storrs FJ. Psoralen plus UVA protocol for Compositae photosensitivity. *Am J Contact Dermat* 1996; **7**:171-6.
- 94 Yokel BK, Hood AF, Morison WL. Management of chronic photosensitive eczema. *Arch Dermatol* 1990; **126**:1283-5.
- 95 Parrish JA, Jaenicke KF, Morison WL *et al.* Solar urticaria: treatment with PUVA and mediator inhibitors. *Br J Dermatol* 1982; **106**:575-80.
- 96 Adamski H, Bedane C, Bonnevalle A *et al.* Solar urticaria treated with intravenous immunoglobulins. *J Am Acad Dermatol* 2011; **65**:336-40.
- 97 Hudson-Peacock MJ, Farr PM, Diffey BL *et al.* Combined treatment of solar urticaria with plasmapheresis and PUVA. *Br J Dermatol* 1993; **128**:440-2.
- 98 Leenutaphong V, Hölzle E, Plewig G *et al.* Plasmapheresis in solar urticaria. *Dermatologica* 1991; **182**:35-8.
- 99 Bilsland D, Ferguson J. A comparison of cetirizine and terfenadine in the management of solar urticaria. *Photodermatol Photoimmunol Photomed* 1991; **8**:62-4.
- 100 Diffey BL, Farr PM. Treatment of solar urticaria with terfenadine. *Photodermatol* 1988; **5**:25-9.
- 101 Grundmann SA, Ständer S, Luger TA *et al.* Antihistamine combination treatment for solar urticaria. *Br J Dermatol* 2008; **158**:1384-6.
- 102 Grattan CE, Humphreys F. Guidelines for evaluation and management of urticaria in adults and children. *Br J Dermatol* 2007; **157**:1116-23.
- 103 Calzavara-Pinton P, Zane C, Rossi M *et al.* Narrowband ultraviolet B phototherapy is a suitable treatment option for solar urticaria. *J Am Acad Dermatol* 2012; **67**:e5-9.
- 104 Wolf R, Herzinger T, Grahovac M *et al.* Solar urticaria: long-term rush hardening by inhibition spectrum narrow-band UVB 311 nm. *Clin Exp Dermatol* 2013; **38**:446-7.
- 105 Collins P, Ferguson J. Narrow-band UVB (TL-01) phototherapy: an effective preventative treatment for the photodermatoses. *Br J Dermatol* 1995; **132**:956-63.
- 106 Bernhard JD, Jaenicke K, Momtaz-T K *et al.* Ultraviolet A phototherapy in the prophylaxis of solar urticaria. *J Am Acad Dermatol* 1984; **10**:29-33.
- 107 Dawe RS, Ferguson J. Prolonged benefit following ultraviolet A phototherapy for solar urticaria. *Br J Dermatol* 1997; **137**:144-8.
- 108 Beissert S, Ständer H, Schwarz T. UVA rush hardening for the treatment of solar urticaria. *J Am Acad Dermatol* 2000; **42**:1030-2.
- 109 Roelandts R. Pre-PUVA UVA desensitization for solar urticaria. *Photo-dermatology* 1985; **2**:174-6.
- 110 Roelandts R. Photo(chemo)therapy and general management of erythropoietic protoporphyria. *Dermatology* 1995; **190**:330-1.

- 111 Ros AM. PUVA therapy for erythropoietic protoporphyria. *Photo-dermatology* 1988; **5**:148-9.
- 112 Warren LJ, George S. Erythropoietic protoporphyria treated with narrow-band (TL-01) UVB phototherapy. *Australas J Dermatol* 1998; **39**:179-82.
- 113 Sivaramakrishnan M, Woods J, Dawe R. Narrowband ultraviolet B phototherapy in erythropoietic protoporphyria: case series. *Br J Dermatol* 2014; **170**:987-8.
- 114 Gschnait F, Schwarz T, Ladich I. Treatment of polymorphous light eruption. *Arch Dermatol Res* 1983; **275**:379-82.
- 115 Halpern SM, Anstey AV, Dawe RS *et al*. Guidelines for topical PUVA: a report of a workshop of the British photodermatology group. *Br J Dermatol* 2000; **142**:22-31.
- 116 Konya J, Diffey BL, Hindson TC. Time course of activity of topical 8-methoxypsoralen on palmoplantar skin. *Br J Dermatol* 1992; **127**:654-6.
- 117 Rosén K, Mobacken H, Swanbeck G. Chronic eczematous dermatitis of the hands: a comparison of PUVA and UVB treatment. *Acta Derm Venereol* 1987; **67**:48-54.
- 118 Rosén K, Jontell M, Mobacken H *et al*. Epidermal Langerhans' cells in chronic eczematous dermatitis of the palms treated with PUVA and UVB. *Acta Derm Venereol* 1989; **69**:200-5.
- 119 Mobacken H, Rosén K, Swanbeck G. Oral psoralen photochemotherapy (PUVA) of hyperkeratotic dermatitis of the palms. *Br J Dermatol* 1983; **109**:205-8.
- 120 Tegner E, Thelin I. PUVA treatment of chronic eczematous dermatitis of the palms and soles. *Acta Derm Venereol* 1985; **65**:451-3.
- 121 Morison WL, Parrish JA, Fitzpatrick TB. Oral methoxsalen photochemotherapy of recalcitrant dermatoses of the palms and soles. *Br J Dermatol* 1978; **99**:293-302.
- 122 LeVine MJ, Parrish JA, Fitzpatrick TB. Oral methoxsalen photochemotherapy (PUVA) of dyshidrotic eczema. *Acta Derm Venereol* 1981; **61**:570-1.
- 123 De Rie MA, Van Eendenburg JP, Versnick AC *et al*. A new psoralen-containing gel for topical PUVA therapy: development, and treatment results in patients with palmoplantar and plaque-type psoriasis, and hyperkeratotic eczema. *Br J Dermatol* 1995; **132**:964-9.
- 124 Schempp CM, Müller H, Czech W *et al*. Treatment of chronic palmoplantar eczema with local bath-PUVA therapy. *J Am Acad Dermatol* 1997; **36**:733-7.
- 125 Gritiyarangsarn P, Sukhum A, Tresukosol P *et al*. Topical PUVA therapy for chronic hand eczema. *J Dermatol* 1998; **25**:299-301.
- 126 Behrens S, von Kobyletzki G, Gruss C *et al*. PUVA-bath photochemotherapy (PUVA-soak therapy) of recalcitrant dermatoses of the palms and soles. *Photodermatol Photoimmunol Photomed* 1999; **15**:47-51.
- 127 Davis MD, McEvoy MT, el-Azhary RA. Topical psoralen-ultraviolet A therapy for palmoplantar dermatoses: experience with 35 consecutive patients. *Mayo Clin Proc* 1998; **73**:407-11.
- 128 Taylor CR, Baron ED. Hand and foot PUVA soaks: an audit of the Massachusetts General Hospital's experience from 1994 to 1998. *Photodermatol Photoimmunol Photomed* 1999; **15**:188-92.
- 129 Douwes KE, Karrer S, Abels C *et al*. Does smoking influence the efficacy of bath-PUVA therapy in chronic palmoplantar eczema? *Photodermatol Photoimmunol Photomed* 2000; **16**:25-9.
- 130 O'Kane D, McLoone NM, Jenkinson H *et al*. Efficacy of topical PUVA soaks for palmoplantar dermatoses: an audit. *Photodermatol Photoimmunol Photomed* 2008; **24**:279-84.
- 131 Riad K, Felix P, Dorit S *et al*. The use of topical PUVA for palmoplantar dermatoses. *J Dermatolog Treat* 2006; **17**:304-7.
- 132 Grundmann-Kollmann M, Behrens S, Peter RU *et al*. Treatment of severe recalcitrant dermatoses of the palms and soles with PUVA-bath versus PUVA-cream therapy. *Photodermatol Photoimmunol Photomed* 1999; **15**:87-9.

- 133 Shephard SE, Schregenerberger N, Dummer R *et al.* Comparison of 8-MOP aqueous bath and 8-MOP ethanolic lotion (Meladinine) in local PUVA therapy. *Dermatology* 1998; **197**:25-30.
- 134 Schiener R, Gottlöber P, Müller B *et al.* PUVA-gel vs. PUVA-bath therapy for severe recalcitrant palmoplantar dermatoses. A randomized, single-blinded prospective study. *Photodermatol Photoimmunol Photomed* 2005; **21**:62-7.
- 135 Grattan CE, Carmichael AJ, Shuttleworth GJ *et al.* Comparison of topical PUVA with UVA for chronic vesicular hand eczema. *Acta Derm Venereol* 1991; **71**:118-22.
- 136 Engin B, Oguz O. Evaluation of time-dependent response to psoralen plus UVA (PUVA) treatment with topical 8-methoxypsoralen (8-MOP) gel in palmoplantar dermatoses. *Int J Dermatol* 2005; **44**:337-9.
- 137 Adıgen E, Tekin O, Gulekon A *et al.* A retrospective analysis of treatment responses of palmoplantar psoriasis in 114 patients. *J Eur Acad Dermatol Venereol* 2009; **23**:814-9.
- 138 Redon E, Bursztejn AC, Loos C *et al.* [A retrospective efficacy and safety study of UVB-TL01 phototherapy and PUVA therapy in palmoplantar psoriasis]. *Ann Dermatol Venereol* 2010; **137**:597-603.
- 139 Wilkinson JD, Ralfs IG, Harper JI *et al.* Topical methoxsalen photochemotherapy in the treatment of palmoplantar pustulosis and psoriasis. *Acta Derm Venereol Suppl* 1979; **59**:193-8.
- 140 Abel EA, Goldberg LH, Farber EM. Treatment of palmoplantar psoriasis with topical methoxsalen plus long-wave ultraviolet light. *Arch Dermatol* 1980; **116**:1257-61.
- 141 Coleman WR, Lowe NJ, David M *et al.* Palmoplantar psoriasis: experience with 8-methoxypsoralen soaks plus ultraviolet A with the use of a high-output metal halide device. *J Am Acad Dermatol* 1989; **20**:1078-82.
- 142 Gómez MI, Pérez B, Harto A *et al.* 8-MOP bath PUVA in the treatment of psoriasis: Clinical results in 42 patients. *J Dermatolog Treat* 1996; **7**:11-2.
- 143 Chen X, Yang M, Cheng Y *et al.* Narrow-band ultraviolet B phototherapy versus broadband ultraviolet B or psoralen-ultraviolet A photochemotherapy for psoriasis. *Cochrane Database Syst Rev* 2013; **10**:CD009481.
- 144 Murray D, Corbett MF, Warin AP. A controlled trial of photochemotherapy for persistent palmoplantar pustulosis. *Br J Dermatol* 1980; **102**:659-63.
- 145 Rosén K, Mobacken H, Swanbeck G. PUVA, etretinate, and PUVA-etretinate therapy for pustulosis palmoplantaris. A placebo-controlled comparative trial. *Arch Dermatol* 1987; **123**:885-9.
- 146 Layton AM, Sheehan-Dare R, Cunliffe WJ. A double-blind, placebo-controlled trial of topical PUVA in persistent palmoplantar pustulosis. *Br J Dermatol* 1991; **124**:581-4.
- 147 Matsunami E, Takashima A, Mizuno N *et al.* Topical PUVA, etretinate, and combined PUVA and etretinate for palmoplantar pustulosis: comparison of therapeutic efficacy and the influences of tonsillar and dental focal infections. *J Dermatol* 1990; **17**:92-6.
- 148 Lassus A, Lauharanta J, Eskelinen A. The effect of etretinate compared with different regimens of PUVA in the treatment of persistent palmoplantar pustulosis. *Br J Dermatol* 1985; **112**:455-9.
- 149 Marsland AM, Chalmers RJ, Hollis S *et al.* Interventions for chronic palmoplantar pustulosis. *Cochrane Database Syst Rev* 2006:CD001433.
- 150 van Coevorden AM, Kamphof WG, van Sonderen E *et al.* Comparison of oral psoralen-UV-A with a portable tanning unit at home vs hospital-administered bath psoralen-UV-A in patients with chronic hand eczema: An open-label randomized controlled trial of efficacy. *Arch Dermatol* 2004; **140**:1463-6.
- 151 Tzaneva S, Kittler H, Thallinger C *et al.* Oral vs. bath PUVA using 8-methoxypsoralen for chronic palmoplantar eczema. *Photodermatol Photoimmunol Photomed* 2009; **25**:101-5.
- 152 Hawk JL, Grice PL. The efficacy of localized PUVA therapy for chronic hand and foot dermatoses. *Clin Exp Dermatol* 1994; **19**:479-82.

- 153 Hofer A, Fink-Puches R, Kerl H *et al.* Paired comparison of bathwater versus oral delivery of 8-methoxypsoralen in psoralen plus ultraviolet: A therapy for chronic palmoplantar psoriasis. *Photodermatol Photoimmunol Photomed* 2006; **22**:1-5.
- 154 Tupker RA, Coenraads PJ, Zanen P *et al.* Randomized controlled observer-blinded treatment of chronic foot eczema with iontophoresis and bath-PUVA. *Acta Derm Venereol* 2013; **93**:456-60.
- 155 Lawrence CM, Marks J, Parker S *et al.* A comparison of PUVA-etretinate and PUVA-placebo for palmoplantar pustular psoriasis. *Br J Dermatol* 1984; **110**:221-6.
- 156 Norris PG, Hawk JLM, Baker C. British Photodermatology Group guidelines for PUVA. *Br J Dermatol* 1994; **130**:246-55.
- 157 Melski JW, Tanenbaum L, Parrish JA *et al.* Oral methoxsalen photochemotherapy for the treatment of psoriasis: a cooperative clinical trial. *J Invest Dermatol* 1977; **68**:328-35.
- 158 Henseler T, Wolff K, Hönigsmann H *et al.* Oral 8-methoxypsoralen photochemotherapy of psoriasis. The European PUVA study: a cooperative study among 18 European centres. *Lancet* 1981; **1**:853-7.
- 159 Wolff K. Side-effects of psoralen photochemotherapy (PUVA). *Br J Dermatol* 1990; **122**:S117-25.
- 160 Tanew A, Ortel B, Rappersberger K *et al.* 5-Methoxypsoralen (Bergapten) for photochemotherapy. Bioavailability, phototoxicity, and clinical efficacy in psoriasis of a new drug preparation. *J Am Acad Dermatol* 1988; **18**:333-8.
- 161 Berroeta L, Attili S, Wong A *et al.* Time course for development of psoralen plus ultraviolet A erythema following oral administration of 5-methoxypsoralen. *Br J Dermatol* 2009; **160**:717-9.
- 162 Kersch M, Gruss C, von Kobyletzki G *et al.* Time course of 8-MOP-induced skin photosensitization in PUVA bath photochemotherapy. *Br J Dermatol* 1997; **136**:473-4.
- 163 Gruss C, Behrens S, von Kobyletzki G *et al.* Effects of water temperature on photosensitization in bath-PUVA therapy with 8-methoxypsoralen. *Photodermatol Photoimmunol Photomed* 1998; **14**:145-7.
- 164 George SA, Ferguson J. Liquid formulations of 8-methoxypsoralen (8-MOP) and 5-MOP: a prospective double-blind crossover assessment of acute non-phototoxic adverse effects. *Photodermatol Photoimmunol Photomed* 1992; **9**:33-5.
- 165 Wainwright NJ, George S, Ferguson J. Phototoxicity at unusual sites during photochemotherapy. *Clin Exp Dermatol* 1993; **18**:292.
- 166 Suliman MT, Abdolmoneim M. Severe burns following phototherapy with PUVA for vitiligo: a preventable complication that still happening. *Burns* 2005; **31**:1063.
- 167 Verma SB, Wollina U. Accidental PUVA burns, vitiligo and atopic diathesis resulting in prurigo nodularis: a logical but undocumented rarity. *An Bras Dermatol* 2012; **87**:891-3.
- 168 Laube S, George SA. Adverse effects with PUVA and UVB phototherapy. *J Dermatolog Treat* 2001; **12**:101-5.
- 169 Fujii N, Uetsu N, Hamakawa M *et al.* Chronic actinic dermatitis developed during phototherapy for psoriasis. *Photodermatol Photoimmunol Photomed* 2002; **18**:157-9.
- 170 Pirner K, Rubbert A, Salinger R *et al.* [Significance of ultraviolet light in the pathogenesis of systemic lupus erythematosus: case report and discussion of the literature]. *Z Rheumatol* 1992; **51**:20-4.
- 171 Dowdy MJ, Nigra TP, Barth WF. Subacute cutaneous lupus erythematosus during PUVA therapy for psoriasis: case report and review of the literature. *Arthritis Rheum* 1989; **32**:343-6.
- 172 McFadden N. PUVA-induced lupus erythematosus in a patient with polymorphous light eruption. *Photodermatol* 1984; **1**:148-50.
- 173 Puig L, de Moragas JM. Enhancement of PUVA phototoxic effects following celery ingestion: cool broth also can burn. *Arch Dermatol* 1994; **130**:809-10.
- 174 Boffa MJ, Gilmour E, Ead RD. Celery soup causing severe phototoxicity during PUVA therapy. *Br J Dermatol* 1996; **135**:334.

- 175 Bendriss EK, Bechtel Y, Bendriss A *et al.* Inhibition of caffeine metabolism by 5-methoxypsoralen in patients with psoriasis. *Br J Clin Pharmacol* 1996; **41**:421-4.
- 176 Mays DC, Camisa C, Cheney P *et al.* Methoxsalen is a potent inhibitor of the metabolism of caffeine in humans. *Clin Pharmacol Ther* 1987; **42**:621-6.
- 177 Tantcheva Poór I, Servera-Llaneras M, Scharffetter-Kochanek K *et al.* Liver cytochrome P450 CYP1A2 is markedly inhibited by systemic but not by bath PUVA in dermatological patients. *Br J Dermatol* 2001; **144**:1127-32.
- 178 Stephens RB, Cooper A. Hepatitis from 5-methoxypsoralen occurring in a patient with previous flucloxacillin hepatitis. *Australas J Dermatol* 1999; **40**:217-9.
- 179 Berg M, Ros AM. Treatment of psoriasis with psoralens and ultraviolet A. A double-blind comparison of 8-methoxypsoralen and 5-methoxypsoralen. *Photodermatol Photoimmunol Photomed* 1994; **10**:217-20.
- 180 Bjellerup M, Bruze M, Hansson A *et al.* Liver injury following administration of 8-methoxypsoralen during PUVA therapy. *Acta Derm Venereol* 1979; **59**:371-2.
- 181 Freeman K, Warin AP. Deterioration of liver function during PUVA therapy. *Photodermatology* 1984; **1**:147-8.
- 182 Markin RS, Donovan JP, Shaw BW *et al.* Fulminant hepatic failure after methotrexate and PUVA therapy for psoriasis. *J Clin Gastroenterol* 1993; **17**:311-3.
- 183 Pariser DM, Wyles RJ. Toxic hepatitis from oral methoxsalen photochemotherapy (PUVA). *J Am Acad Dermatol* 1980; **3**:248-50.
- 184 Hann SK, Park YK, Im S *et al.* The effect on liver transaminases of phototoxic drugs used in systemic photochemotherapy. *J Am Acad Dermatol* 1992; **26**:646-8.
- 185 Park YM, Kim TY, Kim HO *et al.* Reproducible elevation of liver transaminases by topical 8-methoxypsoralen. *Photodermatol Photoimmunol Photomed* 1994; **10**:261-3.
- 186 Tegner E. Severe skin pain after PUVA treatment. *Acta Derm Venereol* 1979; **59**:467-70.
- 187 Johansson O. "PUVA-induced skin pain"--speculations from a neuroscientist. *Exp Dermatol* 1994; **3**:95-6.
- 188 Norris PG, Maurice PD, Schott GD *et al.* Persistent skin pain after PUVA. *Clin Exp Dermatol* 1987; **12**:403-5.
- 189 Jordan WP. PUVA, pruritus, and the loss of the axon flare. *Arch Dermatol* 1979; **115**:636.
- 190 Burrows NP, Norris PG. Treatment of PUVA-induced skin pain with capsaicin. *Br J Dermatol* 1994; **131**:584-5.
- 191 Zamiri M, Bilsland D. Treatment of bath PUVA-induced skin pain with gabapentin. *Br J Dermatol* 2004; **151**:516-7.
- 192 Roelandts R, Stevens A. PUVA-induced itching and skin pain. *Photodermatol Photoimmunol Photomed* 1990; **7**:141-2.
- 193 Takashima A, Yamamoto K, Kimura S *et al.* Allergic contact and photocontact dermatitis due to psoralens in patients with psoriasis treated with topical PUVA. *Br J Dermatol* 1991; **124**:37-42.
- 194 Legat FJ, Wolf P, Kränke B. Anaphylaxis to 5-methoxypsoralen during photochemotherapy. *Br J Dermatol* 2001; **145**:821-2.
- 195 Park JY, Rim JH, Choe YB *et al.* Anaphylaxis to 8-methoxypsoralen during photochemotherapy. *Photodermatol Photoimmunol Photomed* 2003; **19**:37-8.
- 196 Ramsay B, Marks JM. Bronchoconstriction due to 8-methoxypsoralen. *Br J Dermatol* 1988; **119**:83-6.
- 197 Wennersten G. Exacerbation of bronchial asthma during photochemotherapy with 8-methoxypsoralen and UVA (PUVA). *Photodermatol* 1987; **4**:212-3.
- 198 Dromgoole SH. Bronchial reactions during psoralens and ultraviolet A (PUVA) therapy. *J Am Acad Dermatol* 1984; **11**:894.
- 199 Anderson CD, Frodin T, Skogh M. Unusual adverse effects of 8-methoxypsoralen: bronchial reaction during photochemotherapy (PUVA). *J Am Acad Dermatol* 1984; **10**:298.

- 200 Vázquez-López F, Pérez-Oliva N. Transient hyperpigmentation after calcipotriol ointment and PUVA therapy in psoriatic patients. *Acta Derm Venereol* 1996; **76**:400.
- 201 Gläser R, Röwert J, Mrowietz U. Hyperpigmentation due to topical calcipotriol and photochemotherapy in two psoriatic patients. *Br J Dermatol* 1998; **139**:148-51.
- 202 Carlin CS, Florell SR, Krueger GG. Induction of dramatic hyperpigmentation in a patient with generalized lichen planus treated with re-PUVA. *J Cutan Med Surg* 2002; **6**:125-7.
- 203 Jeanmougin M, Manciet JR, Castelneau JP *et al.* [Systemic photoallergy induced by methoxalen]. *Ann Dermatol Venereol* 1992; **119**:277-80.
- 204 Morgan JM, Weller R, Adams SJ. Onycholysis in a case of atopic eczema treated with PUVA photochemotherapy. *Clin Exp Dermatol* 1992; **17**:65-6.
- 205 McGeorge BC. Lunula change induced by psoralen plus ultraviolet A radiation. *Photodermatol Photoimmunol Photomed* 1992; **9**:15-6.
- 206 Maravić N, Bogdanić V, Aurer I *et al.* Severe hyperlipidemia following treatment with PUVA for acute skin GVHD. *Bone Marrow Transplant* 1994; **14**:173.
- 207 Wilczek A, Sticherling M. Concomitant psoriasis and bullous pemphigoid: Coincidence or pathogenic relationship? *Int J Dermatol* 2006; **45**:1353-7.
- 208 Kao CL, Krathen RA, Wolf JE *et al.* Psoralen plus ultraviolet A-induced bullous pemphigoid. *J Drugs Dermatol* 2008; **7**:695-6.
- 209 Riyaz N, Nasir N, Bindu V *et al.* Bullous pemphigoid induced by topical PUVASOL. *Indian J Dermatol Venereol Leprol* 2014; **80**:363-4.
- 210 Nanda S, Grover C, Reddy BS. PUVA-induced lichen planus. *J Dermatol* 2003; **30**:151-3.
- 211 Kuramoto N, Kishimoto S, Shibagaki R *et al.* PUVA-induced lichen planus pemphigoides. *Br J Dermatol* 2000; **142**:509-12.
- 212 Kivanc MT, Klaus MV, Nashel DJ. Reversible polymyositis occurring during psoralen and ultraviolet A (PUVA) therapy. *J Rheumatol* 2000; **27**:1823-4.
- 213 van Coevorden AM, Coenraads PJ. Severe influenzalike symptoms associated with methoxsalen photochemotherapy. *Arch Dermatol* 2002; **138**:840-1.
- 214 Wolf P, Cerroni L, Smolle J *et al.* PUVA-induced lymphomatoid papulosis in a patient with mycosis fungoides. *J Am Acad Dermatol* 1991; **25**:422-6.
- 215 Vernassière C, Petitpain N, Martin S *et al.* 8-methoxypsoralen and neurological disorders: From dysosmia to migraine. *Photodermatol Photoimmunol Photomed* 2006; **22**:217-8.
- 216 Martin S, Petitpain N, Tréchet P *et al.* 8-Methoxypsoralen-induced dysosmia. *Photodermatol Photoimmunol Photomed* 2003; **19**:213-4.
- 217 Hönigsmann H, Wolff K, Fitzpatrick TB. Oral photochemotherapy with psoralens and UVA (PUVA): principles and practice. In: *Dermatology in general medicine, 3rd ed* (Fitzpatrick TB, Eisen AZ, Wolff K, eds). New York: McGraw-Hill. 1987; 1533-58.
- 218 Fernandes S, Marques Pinto G, Cardoso J. Development of new lesions: a complication of psoralen plus ultraviolet A light therapy for mycosis fungoides. *Photodermatol Photoimmunol Photomed* 2012; **28**:278-9.
- 219 Sage E, Bredberg A. Damage distribution and mutation spectrum: the case of 8-methoxypsoralen plus UVA in mammalian cells. *Mutat Res* 1991; **263**:217-22.
- 220 Peritz AE, Gasparro FP. Psoriasis, PUVA, and skin cancer--molecular epidemiology: the curious question of T-->A transversions. *J Invest Dermatol Symp Proc* 1999; **4**:11-6.
- 221 Gasparro FP, Liao B, Foley PJ *et al.* Psoralen photochemotherapy, clinical efficacy, and photomutagenicity: the role of molecular epidemiology in minimizing risks. *Environ Mol Mutagen* 1998; **31**:105-12.
- 222 Roelandts R. Mutagenicity and carcinogenicity of methoxsalen plus UV-A. *Arch Dermatol* 1984; **120**:662-9.
- 223 Young AR. Photocarcinogenicity of psoralens used in PUVA treatment: present status in mouse and man. *J Photochem Photobiol B Biol* 1990; **6**:237-47.

- 224 Moscicki RA, Morison WL, Parrish JA *et al.* Reduction of the fraction of circulating helper-inducer T cells identified by monoclonal antibodies in psoriatic patients treated with long-term psoralen/ultraviolet-A radiation (PUVA). *J Invest Dermatol* 1982; **79**:205-8.
- 225 Friedmann PS. Disappearance of epidermal Langerhans cells during PUVA therapy. *Br J Dermatol* 1981; **105**:219-21.
- 226 Vella Briffa D, Parker D, Tosca N *et al.* The effect of photochemotherapy (PUVA) on cell mediated immunity in the guinea pig. *J Invest Dermatol* 1981; **77**:377-80.
- 227 Toyota N, Kitamura Y, Ogawa K. Administration of 8-methoxypsoralen and ultraviolet A irradiation (PUVA) induces turnover of mast cells in the skin of C57BL/6 mice. *J Invest Dermatol* 1990; **95**:353-8.
- 228 Viander M, Jansén CT, Eskola J. Influence of whole-body PUVA treatments on human peripheral blood NK cell activity. *Photodermatology* 1984; **1**:23-9.
- 229 Stern RS, Thibodeau LA, Kleiner RA *et al.* Risk of cutaneous carcinoma in patients treated with oral methoxsalen photochemotherapy for psoriasis. *N Engl J Med* 1979; **300**:809-13.
- 230 Stern RS, Laird N, Melski J *et al.* Cutaneous squamous-cell carcinoma in patients treated with PUVA. *N Engl J Med* 1984; **310**:1156-61.
- 231 Stern RS, Lange R. Non-melanoma skin cancer occurring in patients treated with PUVA five to ten years after first treatment. *J Invest Dermatol* 1988; **91**:120-4.
- 232 Lindelöf B, Sigurgeirsson B, Tegner E *et al.* PUVA and cancer: a large-scale epidemiological study. *Lancet* 1991; **338**:91-3.
- 233 Bruynzeel I, Bergman W, Hartevelt HM *et al.* 'High single-dose' European PUVA regimen also causes an excess of non-melanoma skin cancer. *Br J Dermatol* 1991; **124**:49-55.
- 234 Lever LR, Farr PM. Skin cancers or premalignant lesions occur in half of high-dose PUVA patients. *Br J Dermatol* 1994; **131**:215-9.
- 235 Lim JL, Stern RS. High levels of ultraviolet B exposure increase the risk of non-melanoma skin cancer in psoralen and ultraviolet A-treated patients. *J Invest Dermatol* 2005; **124**:505-13.
- 236 Fitzsimons CP, Long J, MacKie RM. Synergistic carcinogenic potential of methotrexate and PUVA in psoriasis. *Lancet* 1983; **1**:235-6.
- 237 Stern RS, Laird N. The carcinogenic risk of treatments for severe psoriasis. Photochemotherapy Follow-up Study. *Cancer* 1994; **73**:2759-64.
- 238 Marcil I, Stern RS. Squamous-cell cancer of the skin in patients given PUVA and ciclosporin: nested cohort crossover study. *Lancet* 2001; **358**:1042-5.
- 239 Hönigsmann H, Wolff K, Gschnait F *et al.* Keratoses and nonmelanoma skin tumors in long-term photochemotherapy (PUVA). *J Am Acad Dermatol* 1980; **3**:406-14.
- 240 Lassus A, Reunala T, Idänpää-Heikkilä J *et al.* PUVA treatment and skin cancer: A follow-up study. *Acta Derm Venereol* 1981; **61**:141-5.
- 241 Henseler T, Christophers E, Hönigsmann H *et al.* Skin tumors in the European PUVA Study. Eight-year follow-up of 1,643 patients treated with PUVA for psoriasis. *J Am Acad Dermatol* 1987; **16**:108-16.
- 242 Mali-Gerrits MG, Gaasbeek D, Boezeman J *et al.* Psoriasis therapy and the risk of skin cancers. *Clin Exp Dermatol* 1991; **16**:85-9.
- 243 Harwood CA, Spink PJ, Suretheran T *et al.* Detection of human papillomavirus DNA in PUVA-associated non-melanoma skin cancers. *J Invest Dermatol* 1998; **111**:123-7.
- 244 Rübber A, Baron JM, Grussendorf-Conen EI. Demonstration of human papillomavirus type 16-related DNA and absence of detectable p53 gene mutations in widespread cutaneous squamous cell carcinomas after oral psoralen with UV-A treatment. *Arch Dermatol* 1996; **132**:1257-9.
- 245 Weissenborn SJ, Höpfel R, Weber F *et al.* High prevalence of a variety of epidermodysplasia verruciformis-associated human papillomaviruses in psoriatic skin of patients treated or not treated with PUVA. *J Invest Dermatol* 1999; **113**:122-6.



- 246 Zumtobel U, Schwarze HP, Favre M *et al.* Widespread cutaneous carcinomas associated with human papillomaviruses 5, 14 and 20 after introduction of methotrexate in two long-term PUVA-treated patients. *Dermatology* 2001; **202**:127-30.
- 247 Stern RS, Nichols KT, Väkevä LH. Malignant melanoma in patients treated for psoriasis with methoxsalen (psoralen) and ultraviolet A radiation (PUVA). The PUVA Follow-Up Study. *N Engl J Med* 1997; **336**:1041-5.
- 248 Stern RS. The risk of melanoma in association with long-term exposure to PUVA. *J Am Acad Dermatol* 2001; **44**:755-61.
- 249 Lindelöf B, Sigurgeirsson B, Tegner E *et al.* PUVA and cancer risk: the Swedish follow-up study. *Br J Dermatol* 1999; **141**:108-12.
- 250 McKenna KE, Patterson CC, Handley J *et al.* Cutaneous neoplasia following PUVA therapy for psoriasis. *Br J Dermatol* 1996; **134**:639-42.
- 251 Lindelöf B, Sigurgeirsson B, Tegner E *et al.* Comparison of the carcinogenic potential of trioxsalen bath PUVA and oral methoxsalen PUVA: A preliminary report. *Arch Dermatol* 1992; **128**:1341-4.
- 252 Hannuksela-Svahn A, Sigurgeirsson B, Pukkala E *et al.* Trioxsalen bath PUVA did not increase the risk of squamous cell skin carcinoma and cutaneous malignant melanoma in a joint analysis of 944 Swedish and Finnish patients with psoriasis. *Br J Dermatol* 1999; **141**:497-501.
- 253 Stern RS, Lunder EJ. Risk of squamous cell carcinoma and methoxsalen (psoralen) and UV-A radiation (PUVA). A meta-analysis. *Arch Dermatol* 1998; **134**:1582-5.
- 254 Nijsten TE, Stern RS. The increased risk of skin cancer is persistent after discontinuation of psoralen+ultraviolet A: a cohort study. *J Invest Dermatol* 2003; **121**:252-8.
- 255 Forman AB, Roenigk HH, Caro WA *et al.* Long-term follow-up of skin cancer in the PUVA-48 cooperative study. *Arch Dermatol* 1989; **125**:515-9.
- 256 van Praag MC, Bavinck JN, Bergman W *et al.* PUVA keratosis. A clinical and histopathologic entity associated with an increased risk of nonmelanoma skin cancer. *J Am Acad Dermatol* 1993; **28**:412-7.
- 257 Rhodes AR, Stern RS, Melski JW. The PUVA lentigo: an analysis of predisposing factors. *J Invest Dermatol* 1983; **81**:459-63.
- 258 Stern RS. Genital tumors among men with psoriasis exposed to psoralens and ultraviolet A radiation (PUVA) and ultraviolet B radiation. The Photochemotherapy Follow-up Study. *N Engl J Med* 1990; **322**:1093-7.
- 259 Perkins W, Lamont D, MacKie RM. Cutaneous malignancy in males treated with photochemotherapy. *Lancet* 1990; **336**:1248.
- 260 Aubin F, Puzenat E, Arveux P *et al.* Genital squamous cell carcinoma in men treated by photochemotherapy. A cancer registry-based study from 1978 to 1998. *Br J Dermatol* 2001; **144**:1204-6.
- 261 Rhodes AR, Harrist TJ, Momtaz-T K. The PUVA-induced pigmented macule: a lentiginous proliferation of large, sometimes cytologically atypical, melanocytes. *J Am Acad Dermatol* 1983; **9**:47-58.
- 262 Frenk E. Malignant melanoma in a patient with severe psoriasis treated by oral methoxsalen photochemotherapy. *Dermatologica* 1983; **167**:152-4.
- 263 Marx JL, Auerbach R, Possick P *et al.* Malignant melanoma in situ in two patients treated with psoralens and ultraviolet A. *J Am Acad Dermatol* 1983; **9**:904-11.
- 264 Kemmett D, Reshad H, Baker H. Nodular malignant melanoma and multiple squamous cell carcinomas in a patient treated by photochemotherapy for psoriasis. *Br Med J (Clin Res Ed)* 1984; **289**:1498.
- 265 Johnson J. Melanoma and psoralens and ultraviolet A. *J Am Acad Dermatol* 1984; **11**:143.
- 266 Gupta AK, Stern RS, Swanson NA *et al.* Cutaneous melanomas in patients treated with psoralens plus ultraviolet A. A case report and the experience of the PUVA Follow-up Study. *J Am Acad Dermatol* 1988; **19**:67-76.

- 267 Bergner T, Przybilla B. Malignant melanoma in association with phototherapy. *Dermatology* 1992; **184**:59-61.
- 268 Hacıyakupoğlu G, Varinli I, Memişoğlu HR *et al.* PUVA treatment and choroidal malignant melanoma. *Acta Ophthalmol* 1993; **71**:846-9.
- 269 Reseghetti A, Tribbia G, Locati F *et al.* Cutaneous malignant melanoma appearing during photochemotherapy of mycosis fungoides. *Dermatology* 1994; **189**:75-7.
- 270 Wolf P, Schöllnast R, Hofer A *et al.* Malignant melanoma after psoralen and ultraviolet A (PUVA) therapy. *Br J Dermatol* 1998; **138**:1100-1.
- 271 Lindelöf B. Risk of melanoma with psoralen/ultraviolet A therapy for psoriasis. Do the known risks now outweigh the benefits? *Drug Saf* 1999; **20**:289-97.
- 272 Whitmore SE, Morison WL. Melanoma after PUVA therapy for psoriasis. *N Engl J Med* 1997; **337**:502-3.
- 273 Wolff K. Should PUVA be abandoned? *N Engl J Med* 1997; **336**:1090-1.
- 274 Olsen JH, Møller H, Frenzt G. Malignant tumors in patients with psoriasis. *J Am Acad Dermatol* 1992; **27**:716-22.
- 275 Boffetta P, Gridley G, Lindelöf B. Cancer risk in a population-based cohort of patients hospitalized for psoriasis in Sweden. *J Invest Dermatol* 2001; **117**:1531-7.
- 276 Gelfand JM, Berlin J, Van Voorhees A *et al.* Lymphoma rates are low but increased in patients with psoriasis: results from a population-based cohort study in the United Kingdom. *Arch Dermatol* 2003; **139**:1425-9.
- 277 Hannuksela-Svahn A, Pukkala E, Läärä E *et al.* Psoriasis, its treatment, and cancer in a cohort of Finnish patients. *J Invest Dermatol* 2000; **114**:587-90.
- 278 Margolis D, Bilker W, Hennessy S *et al.* The risk of malignancy associated with psoriasis. *Arch Dermatol* 2001; **137**:778-83.
- 279 Stern RS, Väkevä LH. Noncutaneous malignant tumors in the PUVA follow-up study: 1975-1996. *J Invest Dermatol* 1997; **108**:897-900.
- 280 Hansen NE. Development of acute myeloid leukaemia in a patient with psoriasis treated with oral 8-methoxypsoralen and longwave ultraviolet light. *Scand J Haematol* 1979; **22**:57-60.
- 281 Freeman K, Warin AP. Acute myelomonocytic leukaemia developing in a patient with psoriasis treated with oral 8-methoxypsoralen and longwave ultraviolet light. *Clin Exp Dermatol* 1985; **10**:144-6.
- 282 Sheehan-Dare RA, Cotterill JA, Barnard DL. Transformation of myelodysplasia to acute myeloid leukaemia during psoralen photochemotherapy (PUVA) treatment of psoriasis. *Acta Derm Venereol* 1989; **69**:262-4.
- 283 Kwong YL, Au WY, Ng MH *et al.* Acute myeloid leukemia following psoralen with ultraviolet A therapy: a fluorescence in situ hybridization study. *Cancer Genet Cytogenet* 1997; **99**:11-3.
- 284 Stern RS. Lymphoma risk in psoriasis: results of the PUVA follow-up study. *Arch Dermatol* 2006; **142**:1132-5.
- 285 Neumann RA, Knobler RM, Jurecka W *et al.* Disseminated superficial actinic porokeratosis: experimental induction and exacerbation of skin lesions. *J Am Acad Dermatol* 1989; **21**:1182-8.
- 286 Reymond JL, Beani JC, Amblard P. Superficial actinic porokeratosis in a patient undergoing long-term PUVA therapy. *Acta Derm Venereol* 1980; **60**:539-40.
- 287 Hazen PG, Carney JF, Walker AE *et al.* Disseminated superficial actinic porokeratosis: appearance associated with photochemotherapy for psoriasis. *J Am Acad Dermatol* 1985; **12**:1077-8.
- 288 Allen AL, Glaser DA. Disseminated superficial actinic porokeratosis associated with topical PUVA. *J Am Acad Dermatol* 2000; **43**:720-2.
- 289 Ros AM, Wennersten G, Lagerholm B. Long-term photochemotherapy for psoriasis: a histopathological and clinical follow-up study with special emphasis on tumour incidence and behavior of pigmented lesions. *Acta Derm Venereol* 1983; **63**:215-21.
- 290 Swart R, Kenter I, Suurmond D. The incidence of PUVA-induced freckles. *Dermatologica* 1984; **168**:304-5.

- 291 Cox NH, Jones SK, Downey DJ *et al.* Cutaneous and ocular side-effects of oral  
photochemotherapy: results of an 8-year follow-up study. *Br J Dermatol* 1987; **116**:145-  
52.
- 292 Takashima A, Matsunami E, Yamamoto K *et al.* Cutaneous carcinoma and 8-  
methoxypsoralen and ultraviolet A (PUVA) lentigines in Japanese patients with  
psoriasis treated with topical PUVA: a follow-up study of 214 patients. *Photodermatol*  
*Photoimmunol Photomed* 1990; **7**:218-21.
- 293 Gschnait F, Wolff K, Hönigsmann H *et al.* Long-term photochemotherapy:  
histopathological and immunofluorescence observations in 243 patients. *Br J Dermatol*  
1980; **103**:11-22.
- 294 Nagase K, Hirashima N, Koba S *et al.* Acquired dermal melanocytosis induced by  
psoralen plus ultraviolet A therapy. *Acta Derm Venereol* 2012; **92**:691-2.
- 295 Ono T, Egawa K, Kayashima K *et al.* Late onset dermal melanocytosis: an upper back  
variant. *J Dermatol* 1991; **18**:97-103.
- 296 Sator PG, Schmidt JB, Hönigsmann H. Objective assessment of photoageing effects  
using high-frequency ultrasound in PUVA-treated psoriasis patients. *Br J Dermatol*  
2002; **147**:291-8.
- 297 Cox AJ, Abel EA. Epidermal dystrophy. Occurrence after psoriasis therapy with  
psoralen and long-wave ultraviolet light. *Arch Dermatol* 1979; **115**:567-70.
- 298 Lerman S, Megaw J, Willis I. Potential ocular complications from PUVA therapy and  
their prevention. *J Invest Dermatol* 1980; **74**:197-9.
- 299 British Photodermatology Group. British Photodermatology Group guidelines for  
PUVA. *Br J Dermatol* 1994; **130**:246-55.
- 300 Stern RS, Parrish JA, Fitzpatrick TB. Ocular findings in patients treated with PUVA. *J*  
*Invest Dermatol* 1985; **85**:269-73.
- 301 Stern RS. Ocular lens findings in patients treated with PUVA. Photochemotherapy  
Follow-Up-Study. *J Invest Dermatol* 1994; **103**:534-8.
- 302 Malanos D, Stern RS. Psoralen plus ultraviolet A does not increase the risk of cataracts:  
a 25-year prospective study. *J Am Acad Dermatol* 2007; **57**:231-7.
- 303 Calzavara-Pinton PG, Carlino A, Manfredi E *et al.* Ocular side effects of PUVA-treated  
patients refusing eye sun protection. *Acta Derm Venereol Suppl* 1994; **186**:164-5.
- 304 Ullrich SE. Does exposure to UV radiation induce a shift to a Th-2-like immune  
reaction? *Photochem Photobiol* 1996; **64**:254-8.
- 305 Wang CY, Brodland DG, Su WP. Skin cancers associated with acquired  
immunodeficiency syndrome. *Mayo Clin Proc* 1995; **70**:766-72.
- 306 Matz H. Phototherapy for psoriasis: what to choose and how to use: facts and  
controversies. *Clin Dermatol* 2010; **28**:73-80.
- 307 Rodrigues LK, Klencke BJ, Vin-Christian K *et al.* Altered clinical course of malignant  
melanoma in HIV-positive patients. *Arch Dermatol* 2002; **138**:765-70.
- 308 Wilkins K, Turner R, Dolev JC *et al.* Cutaneous malignancy and human  
immunodeficiency virus disease. *J Am Acad Dermatol* 2006; **54**:189-206.
- 309 Lunder EJ, Stern RS. Merkel-cell carcinomas in patients treated with methoxsalen and  
ultraviolet A radiation. *N Engl J Med* 1998; **339**:1247-8.
- 310 Izikson L, Nornhold E, Iyer JG *et al.* Merkel cell carcinoma associated with HIV: review  
of 14 patients. *AIDS* 2011; **25**:119-21.
- 311 Ranki A, Puska P, Mattinen S *et al.* Effect of PUVA on immunologic and virologic  
findings in HIV-infected patients. *J Am Acad Dermatol* 1991; **24**:404-10.
- 312 Horn TD, Morison WL, Farzadegan H *et al.* Effects of psoralen plus UVA radiation  
(PUVA) on HIV-1 in human beings: a pilot study. *J Am Acad Dermatol* 1994; **31**:735-  
40.
- 313 Pechère M, Yerly S, Lemonnier E *et al.* Impact of PUVA therapy on HIV viremia: A pilot  
study. *Dermatology* 1997; **195**:84-5.
- 314 Morison WL. PUVA therapy is preferable to UVB phototherapy in the management of  
HIV-associated dermatoses. *Photochem Photobiol* 1996; **64**:267-8.

- 315 Moseley H, Cox NH, Mackie RM. The suitability of sunglasses used by patients  
following ingestion of psoralen. *Br J Dermatol* 1988; **118**:247-53.
- 316 Moseley H, Jones SK. Clear ultraviolet blocking lenses for use by PUVA patients. *Br J  
Dermatol* 1990; **123**:775-81.
- 317 Diffey BL, Miller JA. A comment on the routine testing of sunglasses in  
photochemotherapy. *Br J Dermatol* 1980; **102**:665-8.
- 318 Deleu H, Roelandts R. Protecting the eye from ultraviolet A radiation during  
photochemotherapy. *Photodermatol Photoimmunol Photomed* 1990; **7**:233-6.
- 319 Otman SG, El-Dars LD, Edwards C *et al*. Eye protection for ultraviolet B phototherapy  
and psoralen ultraviolet A patients. *Photodermatol Photoimmunol Photomed* 2010;  
**26**:143-50.
- 320 Tanew A, Ortel B, Hönigsmann H. Half-side comparison of erythemogenic versus  
suberythemogenic UVA doses in oral photochemotherapy of psoriasis. *J Am Acad  
Dermatol* 1999; **41**:408-13.
- 321 Legat FJ, Hofer A, Quehenberger F *et al*. Reduction of treatment frequency and UVA  
dose does not substantially compromise the antipsoriatic effect of oral psoralen-UVA.  
*J Am Acad Dermatol* 2004; **51**:746-54.
- 322 Weinstein GD, White GM. An approach to the treatment of moderate to severe  
psoriasis with rotational therapy. *J Am Acad Dermatol* 1993; **28**:454-9.
- 323 Morison WL. PUVA combination therapy. *Photodermatology* 1985; **2**:229-36.
- 324 van de Kerkhof PC, de Rooij MJ. Multiple squamous cell carcinomas in a psoriatic  
patient following high-dose photochemotherapy and cyclosporin treatment: response  
to long-term acitretin maintenance. *Br J Dermatol* 1997; **136**:275-8.
- 325 Agnew KL, Bunker CB. Multiple cutaneous squamous carcinoma in a psoriatic  
associated with ciclosporin, alcohol abuse and ultraviolet radiation exposure which  
were suppressed by acitretin. *J Eur Acad Dermatol Venereol* 2003; **17**:113-4.
- 326 Speight EL, Farr PM. Calcipotriol improves the response of psoriasis to PUVA. *Br J  
Dermatol* 1994; **130**:79-82.
- 327 Tzaneva S, Hönigsmann H, Tanew A *et al*. A comparison of psoralen plus ultraviolet A  
(PUVA) monotherapy, tacalcitol plus PUVA and tazarotene plus PUVA in patients with  
chronic plaque-type psoriasis. *Br J Dermatol* 2002; **147**:748-53.
- 328 Cristofolini M, Recchia G, Boi S *et al*. 6-Methylangelicins: new monofunctional  
photochemotherapeutic agents for psoriasis. *Br J Dermatol* 1990; **122**:513-24.
- 329 Ortel B, Perl S, Kinaciyan T *et al*. Comparison of narrow-band (311 nm) UVB and  
broad-band UVA after oral or bath-water 8-methoxypsoralen in the treatment of  
psoriasis. *J Am Acad Dermatol* 1993; **29**:736-40.
- 330 Sakuntabhai A, Diffey BL, Farr PM. Response of psoriasis to psoralen-UVB  
photochemotherapy. *Br J Dermatol* 1993; **128**:296-300.
- 331 Zhao JF, Zhang YJ, Jin XH *et al*. Green tea protects against psoralen plus ultraviolet  
A-induced photochemical damage to skin. *J Invest Dermatol* 1999; **113**:1070-5.
- 332 Middelkamp-Hup MA, Pathak MA, Parrado C *et al*. Orally administered Polypodium  
leucotomos extract decreases psoralen-UVA-induced phototoxicity, pigmentation, and  
damage of human skin. *J Am Acad Dermatol* 2004; **50**:41-9.
- 333 Hudson-Peacock MJ, Angus B, Farr PM. Response of PUVA-induced keratoses to  
etretinate. *J Am Acad Dermatol* 1996; **35**:120-3.
- 334 Diawara MM, Allison T, Kulkosky P *et al*. Psoralen-induced growth inhibition in Wistar  
rats. *Cancer Lett* 1997; **114**:159-60.
- 335 Diawara MM, Chavez KJ, Hoyer PB *et al*. A novel group of ovarian toxicants: the  
psoralens. *J Biochem Mol Toxicol* 1999; **13**:195-203.
- 336 Lam J, Polifka JE, Dohil MA. Safety of dermatologic drugs used in pregnant patients  
with psoriasis and other inflammatory skin diseases. *J Am Acad Dermatol* 2008;  
**59**:295-315.
- 337 Stern RS, Lange R. Outcomes of pregnancies among women and partners of men with  
a history of exposure to methoxsalen photochemotherapy (PUVA) for the treatment of  
psoriasis. *Arch Dermatol* 1991; **127**:347-50.

- 338 Gunnarskog JG, Källén AJ, Lindelöf BG *et al.* Psoralen photochemotherapy (PUVA) and pregnancy. *Arch Dermatol* 1993; **129**:320-3.
- 339 Garbis H, Eléfant E, Bertolotti E *et al.* Pregnancy outcome after periconceptional and first-trimester exposure to methoxsalen photochemotherapy. *Arch Dermatol* 1995; **131**:492-3.
- 340 Yang YW, Chen CS, Chen YH *et al.* Psoriasis and pregnancy outcomes: a nationwide population-based study. *J Am Acad Dermatol* 2011; **64**:71-7.
- 341 Pham CT, Koo JY. Plasma levels of 8-methoxypsoralen after topical paint PUVA. *J Am Acad Dermatol* 1993; **28**:460-6.
- 342 Weatherhead S, Robson SC, Reynolds NJ. Management of psoriasis in pregnancy. *BMJ* 2007; **334**:1218-20.
- 343 Taylor DK, Anstey AV, Coleman AJ *et al.* Guidelines for dosimetry and calibration in ultraviolet radiation therapy: a report of a British Photodermatology Group workshop. *Br J Dermatol* 2002; **146**:755-63.
- 344 Moseley H, Allan D, Amatiello H *et al.* British Association of Dermatologists & British Photodermatology Group guidelines for dosimetry and calibration in ultraviolet radiation therapy 2015. *Br J Dermatol* 2015;(in press).
- 345 Macfarlane L, Bhoyrul B, Ibbotson SH *et al.* Practice when minimal phototoxic and minimal erythema doses are not determinable. *Photodermatol Photoimmunol Photomed* 2015; **31**:224-6.